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1. INTRODUCTION 
1.1 INTRODUCTION` 
 Analytical chemistry may be defined as the science and art of determining the 
composition of materials in terms of elements or compounds contained in them.  In 
analytical chemistry, it is of prime importance to obtain information about the 
qualitative and quantitative comparison of substance and chemical species.   
1.2 UV SPECTROSCOPY  
[A.H. Beckett and J.B. Stenlake, 2005, B.K. Sharma, 2000, chatwal, Willard et.al., 
1986] 
    The technique of ultra violet spectrophotometry is one of the most frequently 
employed methods in Pharmaceutical Analysis. It involves the measurement of the 
amount of UV (400-200nm) radiation absorbed by a substance in solution. When a 
beam of light is passed through a transparent cell containing a solution of an 
absorbing substance, reduction of the intensity of the light occur. 
This is due to 
a) Reflections at the inner and outer surfaces of the cell. 
b) Scatter by particles in the solution. 
c) Absorption of light by molecules in the solution. 
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QUANTITATIVE SPECROPHOTOMETRIC METHODS 
 [A.H.Beckett, and J.B.Stenlake, 2001] 
Preparing a solution in a transparent solvent and measuring its absorbance at a 
suitable wavelength may quickly carry out the assay of an absorbing substance. The 
wavelength normally selected is a wavelength of maximum absorption (λmax) where 
small error in setting the wavelength scale has little effect on the measured 
absorbance. 
Ideally, the concentration should be adjusted to give an absorbance of 
approximately 0.9, around which the accuracy and precision of the measurement are 
optimal. 
1. Use of Standard Absorptivity Value:    
            Absorptivity value A1%1cm or € avoids the need of standard 
solution of reference substance. It is advantageous where it is difficult or 
expensive to get pure sample of reference substance. 
2. Assay of Substances in Multi Component  
   Multi components assays are done by several methods in which 
concentration of interfering substances should be considered which include. 
1. Simultaneous equation method. 
2. Absorbance ratio method. 
3. Derivative spectroscopic.  
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SIMULTANEOUS EQUATION METHOD 
If a sample contains two, absorbing drugs (X and Y) each of which absorbs at 
the λmax of the other as shown in Fig, it may be possible to determine both drugs by 
the technique of simultaneous equations (Vierodt’s method).    
  
 The Information required is:  
a)  The absorptivities of X at λ1 and λ2, ax1 and ax2, respectively  
(b) The absorptivities of Y at λ1 and λ2, ay1 and ay2, respectively  
(c) The absorbance of the diluted sample at λ1 and λ2, A1 and A2 respectively. 
Let Cx and CY, be the concentrations of X and Y respectively in the diluted sample. 
Two equations are constructed based upon the fact that at λ1 and λ2 the 
absorbance of the mixture is the sum of the individual absorbance’s of x and y, 
At λ1  A1 = ax1bcx + ay1bcy  ----------- (1) 
At λ2  A2 = ax2bcx + ay2bcy  ----------- (2) 
For measurement in 1cm cells, b = 1. 
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Rearrange eq. (2) 
  CY = A2– ax2cx 
                                     ay2 
Substituting for CY in eq, (1) and rearranging gives 
  Cx = A2ay1 – A1ay2    (3) 
           ax2ay1 – ax1ay2 
and  Cy = A1ax2 – A2ax1    (4) 
           ax2ay1 – ax1ay2 
As an exercise we should derive modified equations containing a symbol (b) 
for path length, for application in situations where A1 and A2 are measured in cells 
other than 1 cm path length. 
 A2/A1   ay2/ay1 
 Ax2/ax1
          
and  A2/A1  
The criteria are that the ratios should lie outside the range 0.1-2.0 for the 
precise determination of Y and X respectively. An additional criterion is that the two 
components do not interact chemically, thereby negating the initial assumption that 
the total absorbance is the sum of the individual absorbance. 
DERIVATIVE SPECTROPHOTOMETRY 
 Derivative spectrophotometry involves the conversion of a normal spectrum 
to its first, second or higher derivative spectrum. The transformations that occur in the 
derivative spectra are understood by reference to a Gaussian band which represents an 
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ideal absorption band. In the context of derivative spectrophotometry, the normal 
absorption spectrum is referred to as the fundamental, zeroth order or D° spectrum. 
The first derivative (D1) spectrum is a plot of the ratio of change of 
absorbance with wavelength against wavelength, i.e. a plot of the slope of the 
fundamental spectrum against wavelength or a plot of dA/dλ Vs λ. At λ2 and λ4, the 
maximum positive and maximum negative slope respectively in the D°. Spectrums 
correspond with maximum and a minimum respectively in the D1 spectrum. The λmax 
at λ3 is a wavelength of zero slopes and gives dA/d λ 0, i.e. a cross-over point, in the 
D1 spectrum.  
The second derivative (D2) spectrum is a plot of the curvature of the D° 
spectrum against wavelength or a plot of d2A/dλ2 Vs λ.  
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The zeroth (a), first (b) and second (c) derivative spectra of a Gaussian band. 
Wavelengths of maximum slope and zero curvature in the D° spectrum 
correspond with cross-over points in the D2 spectrum. 
In summary, the first derivative spectrum of an absorption band is 
characterized by a maximum, a minimum, and a cross-over point at the λmax of the 
absorption band.  
These spectral transformations confer two principal advantages on derivative 
spectrophotometry. Firstly, an even order spectrum is of narrower spectral bandwidth 
than its fundamental spectrum. Secondly, derivative spectrophotometry discriminates 
in favour of substances of narrow spectral bandwidth against broad bandwidth 
substances. This is because ‘the derivative amplitude (D), i.e. the distance from a 
maximum to a minimum, is inversely proportional to the fundamental spectral 
bandwidth (14’) raised to the power (n) of the derivative order.  
Thus,               D α (1/W) 
Consequently, substances of narrow spectral bandwidth display larger 
derivative amplitudes than those of broad bandwidth substance 
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(a) The individual spectra of two components X and Y in admixture and their 
combined spectrum (b) The second derivative spectrum of the mixture showing 
improved resolution of the individual bands. 
Apart from quantitative analysis, the application of UV is extended to following  
1. Structure determination. 
2. Quantitative analysis→ it is limited because absorption band tend to be  
     broad. 
3. Determination of strength of hydrogen bonding. 
4. Study of charge transfer complexes. 
5. Study of chemical rings 
6.  Study of isomerism.        
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AREA UNDER THE CURVE METHOD (Telekone et al., 2010) 
            The area under curve method involves the calculation of integrated value of 
absorbance with respect to the wavelength between the two selected wavelengths λ1 
and λ2. Area calculation processing item calculates the area bound by the curve and 
the horizontal axis. The horizontal axis is selected by entering the wavelength range 
over which area has to be calculated. This wavelength area is selected on the basis of 
repeated observation so as to get the linearity between area under curve and 
concentration.  In combination drugs λ1 and λ2 denotes the wavelength ranges of the 
components. The integrated value of absorbance in the wavelength ranges of both the 
drugs are substituted in the simultaneous equation to get the concentration of the 
drugs. 
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GEOMERTIC CORRECTION METHOD: 
                A number of mathematical correction procedures have been developed 
which reduce or eliminate the background irrelevant absorption that may be present in 
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samples of biological origin. The simplest of these procedures is the three-point 
geometric procedure, which may be applied if the irrelevant absorption is linear at the 
three wavelengths selected. Consider an absorption spectrum (Fig. a) comprising the 
spectrum of analyte (Fig. b) and that of the background absorption (Fig. c).If the 
wavelengths λ1, λ2 and λ3 are selected so that the background absorbance’s B1, B2, and 
B3 are linear, then the corrected absorbance, D, of the drug may be calculated from 
the three absorbance’s A1, A2, and A3 of the sample solution at λ1, λ2 and λ3 
respectively, as follows. 
   Let vD and wD be the absorbance of the drug alone in the sample solution at λ1 and 
λ3 respectively, i.e. v and w are the absorbance ratios vD/D and wD/D respectively. 
                      Therefore B1 = A1-vD, B2 = A2-D and B3 = A3-wD 
Let y and z be the wavelength intervals (λ2 - λ1) and (λ3 - λ2) respectively. 
Then 
 (Similar triangles) 
                Therefore zB1 = (y + z) B2-yB3 
                             
z (A1 - vD) = (y + z)(A2 - D)-y(A3 –v D) 
Rearranging: 
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Where, 
               y= (λ2-λ1) 
               z= (λ3-λ2) 
               A1= Absorbance of the sample solution at λ1 
              A2= Absorbance of the sample solution at λ2 
             A3= Absorbance of the sample solution at λ3 
             v = vD/D [absorbance ratio of drug in methanol (without serum) at λ1 and λ2] 
             w = wD/D [absorbance ratio of drug in methanol (without serum) at λ3 and λ2] 
                    This is general equation which may be applied in any situation where A1, 
A2 and A3 of the sample, the wavelength intervals y and z and the absorbance ratios v 
and w are known. The values of v and w are determined experimentally using a 
solution of drug only. The concentration of the drug is calculated from the corrected 
absorbance D using any of the normal procedures. 
It should be noted that the three-point correction procedures are simply algebraic 
calculations of what the baseline technique in infrared spectrophotometry does 
graphically. 
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(a)                   (b) 
(c) 
CHROMATOGRAPHY [Willard et al., P.D Sethi 2001] 
Chromatography is differential migration processes where sample components 
are selectively retained by stationary phase. High Performance Liquid 
Chromatography is a convenient separation technique used for wide types of samples 
with exceptional resolving power, speed and nano molecular detection levels. It is an 
analytical chromatographic technique that is useful for separating ions / molecule that 
are dissolved in a solvent 
In this two mutually immiscible phases are brought in to contact one phase is 
stationary and other is mobile. Species in the sample undergo repeated interactions 
(partitions) between the mobile phase & stationary phase. The components are 
gradually separated in to bands in mobile phase. It is an analytical chromatographic 
technique that is useful for separating ions / molecule that are dissolved in a solvent. 
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HIGH PERFORMANCE LIQUID CHROMATOGRAPHY  
              HPLC is a type of liquid chromatography that employs a liquid mobile phase 
and a very finely divided stationary phase. In order to obtain satisfactory flow rate 
liquid must be pressurized to a few thousands of pounds per square inch. 
The rate of distribution of drugs between stationary and mobile phase is 
controlled by diffusion process, if diffusion is minimized, a faster and effective 
separation can be achieved. The technique of high performance liquid 
chromatography is so called because of its improved performance when compared to 
classical column chromatography. Advances in column technology, high-pressure 
pumping system and sensitive detectors have transformed liquid column 
chromatography into high speed, efficient, accurate and highly resolved method of 
separation. 
HPLC BASIC INSTRUMENTATION 
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HIGH PERFORMANCE THINLAYER CHRPMATOGRAPHY: [P.D Sethi 
2001] 
A method which satisfies the basic requirement for qualitative and 
quantitative analysis and also capable of being used by personnel with minimum of 
technical training and under reasonable laboratory facilities, is High Performance 
Thin Layer Chromatography (HPTLC). 
Thin Layer chromatography can be used as a qualitative tool for separation of 
simple mixtures where low cost and simplicity are required, or else it can be used as a 
powerful separation tool for quantitative analysis, the later now referred to as 
HPTLC. It can simultaneously handle several samples even of divergent nature and 
composition, supporting several analyses at a given time. 
Steps involved in HPTLC 
 Step 1: Sample application.      
 The samples to be chromatographed are applied to the chromatogram layer. 
Volume precision and exact positioning are ensured by the use of a suitable 
instrument. 
 Step 2: Chromatogram development 
 The solvent (mobile phase) migrates the predetermined distance in the layer 
(stationary phase) by capillary action. In this process, the samples are separated into 
fractions. After evaporation of the mobile phase, the fractions remain stored on the 
layer.    
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 Step 3: Chromatogram evaluation 
 The tracks (samples) are scanned in a densitometer with a light beam in the 
visible or ultraviolet range of the spectrum. Absorbance or fluorescence is measured 
by diffuse reflectance. Alternatively to classical densitometry, the chromatogram can 
be evaluated by video technology. Additional operations such as per or post-
chromatographic derivatisation can be performed as required. 
HPTLC has become the accepted term for layer which 
• Area slightly thinner than conventional layers (0.20mm instead of 0.25 mm) 
and thus need less sample to show the same measuring result. 
• Have a smaller mean grain size – 7 instead of 12-20 µm and in particular a 
closer grain size distribution than conventional layers. 
• Hence give better resolution with a migration distance about 50% shorter-
50mm as against -120mm. 
•  Have improved optical properties over conventional layers which give better 
accuracy during densitometric evaluation. 
Comparative evaluation of HPTLC and HPLC techniques 
1. Simultaneous analysis of standard and sample on the same chromatoplate 
is possible in HPTLC but it is not possible in HPLC 
2. Low cost pre-coated HPTLC plates are available, whereas HPLC columns 
are very expensive. 
3. Solvents need degassing in HPLC method but HPTLC doesn’t need this. 
4. Mobile phase consumption is extremely low in HPTLC and high in HPLC 
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5. No contamination can occur in HPTLC as fresh plates and mobile phase 
are used for each analysis but contamination occurs in HPLC. 
6. Corrosive and UV absorbing mobile phases can be used in HPTLC but not 
in HPLC. 
7. Substance sensitive to light and oxygen can create problem in HPTLC but 
it does not affect HPLC as it is closed system. 
 
ANALYTICAL METHOD VALIDATION 
              Method validation can be defined as (ICH) “Establishing documented 
evidence, which provides a high degree of assurance that a specific activity will 
consistently produce a desired result or product meeting its predetermined 
specifications and quality characteristics”. Typical validation characteristics which 
should be considered are:     
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Accuracy 
              The accuracy of a method is the closeness of the measured value to the true 
value for the sample.  
         Accuracy criteria for an assay method is that the mean recovery will be 100±2% 
over the range of 80%-120% at the target concentration. For impurity method, the 
mean recovery will be within 0.1% absolute of the theoretical concentration or 10% 
relative, whichever is greater for impurities in the range of 0.1-2.5%v/w. 
Precision 
         The precision of an analytical method is the amount of scatter in the results 
obtained from multiple analysis of a homogeneous sample. To be meaningful, the 
precision study must be performed using the exact sample and standard preparation 
procedures that will be used in the final method. 
         Precision is the measure of the degree of repeatability of analytical method 
under normal operation and is normally expressed as %RSD for the statistically 
significant number of samples. According to ICH, precision should be performed at 
three different levels: 
a) Repeatability 
b) Intermediate precision  
c) Reproducibility 
          Repeatability is the result of method operating over a short interval under same 
conditions (Intra-assay precision) and it should be determined from a minimum of 
nine determinations covering the specified range of procedures (three levels, three 
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repetitions each) or from a minimum of six determinations at 100% of the test or 
target concentration. 
        Intermediate precision is the precision obtained when the assay is performed by 
multiple analysts, using multiple instruments, on multiple days, in one laboratory. 
Different sources of reagents and multiple lots of columns should also be included in 
this study. Intermediate precision results are used to identify which of the above 
factors contribute significant variability to the final result. 
         The last type of precision study is reproducibility, which is determined by 
testing homogeneous samples in multiple laboratories, often as part of inter laboratory 
crossover studies. The evaluation of reproducibility results often focuses more on 
measuring bias in results than on determining differences in precision alone. 
Statistical equivalence is often used as measures of acceptable inter laboratory results.  
          For an assay method, the instrument precision (intermediate precision) will be 
1% and the intra-assay precision (Repeatability) will be 2% and for an impurity 
method, instrument precision will be 5% and intra-assay precision will be 10%. 
Specificity  
Specificity is the ability to assess unequivocally the analyte in the presence of 
components which may be expected to be present. Lack of specificity of an individual 
analytical procedure may be compensated by other supporting analytical procedures. 
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Linearity 
              A linear relationship should be evaluated across the range of the analytical 
procedure. It may be demonstrated directly on the drug substance (by dilution of a 
standard stock solution) and/or separate weightings of synthetic mixtures of the drug 
product components, using the proposed procedure. 
              Linearity study verifies that the sample solutions are in a concentration range 
where analyte response is linearly proportional to the concentration.  
              Five concentration levels from 50-150% of the standard solutions of the 
analyte are required to allow detection of curvature in the plotted data. Generally five 
concentrations ranging from 80-120% of standard concentration should be used in 
three replicates of each concentration. 
              Acceptability of linearity is often judged by correlation co-efficient and y-
intercept of linear regression line for the response versus concentration plot. A 
correlation co-efficient of >0.999 is generally considered as evidence of acceptable fit 
of the data to the regression line. The Y-intercept should be less than a few 
percentage of the response obtained for the analyte at the target level. The 
recommended range for an assay method for content would be RSD ± 20% and the 
range for an assay/impurities combination method based on area % (for impurities) 
would be ± 20% of target concentration down to the limit of quantification of the drug 
substance or impurity.  
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Range 
        Range is the interval between upper and lower levels of analyte that have been 
demonstrated to be determined with precision, accuracy and linearity. Range of an 
analytical method is the concentration interval over which acceptable accuracy, 
linearity and precision are obtained. 
Detection limit  
The detection limit of an individual analytical procedure is the lowest amount 
of analyte in a sample which can be detected but not necessarily quantitated as an 
exact value. 
 Based on the standard deviation of the response and the slope, the detection 
limit (DL) may be expressed as 
S
3.3σDL =
 
Where, 
σ = standard deviation of the response 
S= slope of the calibration curve (of the analyte) 
Quantification limit  
The quantification limit of an analytical procedure is the lowest amount of 
analyte in a sample which can be quantitatively determined with suitable precision, 
accuracy and reliability by the proposed method. 
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Based on the standard deviation of the response and the slope, quantitation 
limit may be expressed as, 
S
10σQL =
 
Where, 
σ = standard deviation of the response  
S = slope of the calibration curve (of the analyte) 
Ruggedness 
         Ruggedness is the degree of reproducibility of test results obtained by analysis 
of same sample under a variety of normal test conditions such as different 
laboratories, different analysts, different instruments, different lots of reagent, 
different elapse assay times, different assay temperatures, different days, etc. It is 
normally expressed as lack of influence on test results of operational and 
environmental variables of the analytical method. 
Robustness 
         ICH defines robustness as a measure of the method's capability to remain 
unaffected by small, but deliberate variations in method parameters. The evaluation 
of robustness should be considered during the development phase and depends on the 
type of procedure under study. It should show the reliability of an analysis with 
respect to deliberate variations in method parameters.  
  In the case of liquid chromatography, examples of typical variations are 
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• Influence of variations of pH in a mobile phase 
• Influence of variations in mobile phase composition 
• Different columns (different lots and/or suppliers) 
•  Temperature 
•  Flow rate. 
System Suitability 
           System suitability is the checking of a system to ensure system performance 
before or during the analysis of unknowns. Before performing any validation 
experiment, you should establish that the HPLC and the procedure are capable of 
providing data of acceptable quality. These tests are to verify that the resolution and 
repeatability of the system are adequate for the analysis to be performed. It is based 
on the concept that equipment, electronics, analytical operations and sample 
constitute an integral system that can be evaluated as a whole. 
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System suitability parameters and recommendations: 
S.No Parameters Recommendations 
1 Theoretical plates (N) >2000 
2 Tailing factor (T) ≤ 2 
3 Resolution (Rs) > 2 between peak of interest and the closest 
eluting potential interference 
4 Repeatability  RSD ≤ 1% for N ≥5 is desirable 
5 Capacity factor (k1) > 2.0 
6 Relative retention Not essential as long as the resolution is stated 
 
SYSTEM SUITABILITY PARAMETERS   
[Lloyd, 1997; A.H. Beckett, and J.B. Stenlake, 2007] 
System suitability testing is an integral part of many analytical procedures. 
The tests are based on the concept that the equipment, electronics, analytical 
operations, and samples to be analyzed constitute an integral system that can be 
evaluated as such. System suitability test parameters to be established for a particular 
procedure depend on the type of procedure being validated.  
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The parameters that are affected by the changes in chromatographic 
conditions are, 
• Column capacity factor (KA) 
• Resolution (Rs) 
• Selectivity (α) 
• Column efficiency (N) and 
• Peak asymmetry factor (As) 
• Tailing factor (T) 
• Height Equivalent to a Theoretical Plate (HETP) 
i) Column capacity factor (KA) 
The retention of a drug with a given packing material and eluent can be 
expressed as retention time or retention volume, but both of these are dependent on 
flow rate, column length and column diameter. The retention is best described as a 
column capacity ratio (K), which is independent of these factors. The column 
capacity ratio of a compound (A) is defined as  
0
0A
0
0A
A t
tt
V
VV
K
−
=
−
=  
Where, 
VA = Elution volume of A 
V0 = Elution volume of a non retained compound (void volume). 
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At constant flow rate, retention times (tA and to) can be used instead of 
retention volumes. Retention data is sometimes expressed, relative to a known 
internal standard (B). The ratio of retention times (tA/tB) can be used, but the ratio of 
adjusted retention times  





−
−
oB
oA
tt
tt
 is better when data need to be transferred 
between different chromatographs. 
The values of k’ of individual bands increase or decrease with changes in 
solvent strength. In reversed phase HPLC, solvent strength increases with the increase 
in the volume of organic phase in the water / organic mobile phase. Typically an 
increase in percentage of the organic phase by 10 % by volume will decrease k’ of the 
bands by a factor of 2-3.  
 
ii) Resolution (Rs) 
The resolution, Rs of two neighboring peaks is defined by the ratio of the 
distance between the two peak maxima. It is the difference between the retention 
times of two solutes divided by their average peak width. For baseline separation, the 
ideal value of Rs is 2.0. It is calculated by using the formula, 
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Where,  
Rt1 and Rt2 are the retention times of components 1 and 2  
W1 and W2 are peak widths of components 1 and 2.   
 
iii)  Selectivity (α) 
The selectivity (or separation factor),α is a measure of relative retention of 
two components in a mixture. The ideal value of selectivity is 2. It can be calculated 
by using the formula,   
01
02
VV
VV
−
−
=α  
Where, V0 is the void volume of the column and V2 and V1 are the retention    
volumes of the second and the first peak, respectively.   
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iv) Column efficiency 
Efficiency (N) of a column is measured by the number of theoretical plates 
per meter. It is a measure of band spreading of a peak. Smaller the band spread, 
higher is the number of theoretical plates, indicating good column and system 
performance. Columns with N ranging from 5,000 to100, 000 plates/meter are ideal 
for a good system. Efficiency is calculated by using the formula, 
2
2
16
W
RtN =  
Where, Rt is the retention time and W is the peak width. 
v) Peak asymmetry factor (As) 
Peak asymmetry factor, As can be used as a criterion of column performance. 
The peak half width b of a peak at 10 % of the peak height, divided by the 
corresponding front half width a gives the asymmetry factor.                                       
Vi) Tailing factor (T) 
           A measure of the symmetry of a peak. 
                                              T = W0.05 / 2f  
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 Where, W0.05 -peak width at 5% height  
          f -distance from peak front to apex point at 5% height.  
         The accuracy of quantification decreases with increase in peak tailing because 
of the difficulties encountered by the integrator in determining where/when the peak 
ends and hence the calculation of the area under the peak.  
Limits-T </= 2 
Vii) Height Equivalent to a Theoretical Plate (HETP) 
A theoretical plate can be of any height, which decides the efficiency of 
separation. If HETP is less the column is more efficient. If HETP is more, the column 
is less efficient. The height equivalent to a theoretical plate (HETP) is given by 
 
STATISTICAL PARAMETERS    
(Sundar Rao, 2006, Sanford Bolton, 1990; Kenneth, 2001; Mendham, 1994)   
Linear regression 
          Linear regression a statistical technique that defines the functional relationship 
between two variable by best-fitting straight line.  Once a linear relationship has been 
shown to have a high probability by the value of the correlation coefficient ‘r’, then 
the best straight line through the data points has to be estimated. This can often be 
done be done by visual inspection of the calibration graph, but in many cases it is far 
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more sensible to evaluate the best straight line by linear regression (the method of 
least squares) 
The equation of straight line is  
y = mx + c 
Where, y the dependent variable is plotted as result of changing x, the independent 
variable. 
         To obtain the regression line ‘y on x’ the slope ‘m’ of the line and the intercept 
‘c’ on the y axis are given by the following equation. 
 
                        N Σxy – (Σx) (Σy)  
m = 
  N Σx2 – (Σx)2 
And 
(Σy) (Σx2) – (Σx) (Σxy) 
c =  
               N Σx2 – (Σx) 2 
Correlation coefficient 
 A measure of the strength of the relationship between two variables is 
provided by the coefficient of correlation, denoted by r, if the relationship between 
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the two variables is of the linear form. It is also called the coefficient of linear 
correlation 
Pearson’s correlation: 
The correlation coefficient calculation for data values should be +1 or -1 
Where the value of  Correlation coefficient is +1 – positive 
Correlation coefficient is -1 – negative  
n Σx1y1 - Σx1y1  
r =  
{[n Σx12 – (Σx1)2] [n Σy12 – (Σy1)2]}1/2 
 
Standard deviation  
It is the square root of the average of the squared deviations of the 
observations. From the arithmetic mean, it is used for measures of dispersion. 
 It is denoted by      
Standard Deviation     =      
1
)( 2
−
−Σ
n
xx
 
 R.S.D (%)  =  100
x
S.D
×    
Where  Σ = Sum of observations 
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x = Mean or arithmetic average (Σx / n) 
x = Individual observed value 
x – x = Deviation of a value from the mean 
n = Number of observations 
Standard error of mean (S.E) 
           The population of standard deviation is not given, but the size of s is large, so 
the sample standard deviation is representing the population of standard deviation. 
S.E. = 
n
S.D
  
Where, 
               S.D = Standard deviation 
                   n = no. of observations  
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2. LITERATURE REVIEW 
(The Merck Index, 2006, www.en.wikipedia.org/wiki/Telmisartan, www.Free 
patents.com, Martindale 2005, British Pharmacopoeia 2009, USP 2007)  
2.1. DRUG PROFILE 
2.1.1. METOPROLOL SUCCINATE                                                        
Molecular Structure  
                                            
O
O
OH
NH
O
HO
O
OH
 
Chemical Name 
            2-propanol, 1-[4-(2-methoxyethyl) phenoxy]-3-[(1-methylethyl) amino]-, (±)-,  
            butanedioate  
Molecular Formula 
            C19H31NO7 
Molecular Weight 
           652.8 g/mol  
Category 
           Cardio selective beta blocker 
Description 
            White or almost white, crystalline powder. 
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Solubility 
           Free soluble in water, soluble in methanol. 
Identification test 
         Melting point: 
                136-137ºC 
        IR spectrum: 
              Principle peak at wave numbers 1516.53, 1052.07, 1072.77, 1187.11 cm-1 
show at fig-1 
pH 
          7.0 - 7.6 
pKa value 
          9.68  
Storage 
           Stored in tightly closed containers in a cool and dry place.  Protected from 
light. 
Pharmacokinetics 
Absorption: 
                   Absorption of Metoprolol is rapid and complete. 
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Distribution:  
                  Plasma levels following oral administration of conventional metoprolol 
tablet, however, approximate 50% of levels following intravenous administration 
indicating 50% first pass metabolism.  
Excretion: 
          Elimination is mainly by biotransformation in the liver and plasms half life 
range from approximately 3 to 7 hours. 
Pharmacological action 
           Metoprolol competes with adrenergic neurotransmitters such as 
catecholamines for binding at beta (1)-adrenergic receptors in the heart and vascular 
smooth muscle. Beta (1)-receptor blockade results in a decrease in heart rate, cardiac 
output, and blood pressure. 
Indications   
                Anti hypertension, anti angina, anti arrhythmic class (II) 
Available Brand  
             Toprol-xl 
             METPURE-XL   
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Adverse effects 
                 Worsening of angina or myocardial infarction, worsening of heart failure, 
worsening of AV block  
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2.1.2. TELMISARTAN 
Molecular Structure   
                                              
O
OH
N
N
N
N
 
Chemical Name 
             4΄-[[4-Methyl-6-(1-methyl-1H-benzimidazol-2-yl)-2-propyl-1H-benzimidazol-
1-yl] ethyl] 
Biphenyl-2-carboxylic acid.  
Molecular Formula 
            C33H30N4O2 
Molecular Weight 
            514.6 g/mol 
Category 
           Angiotensin II type 1 receptors 
Description 
           White or slightly yellowish, crystalline powder. 
Solubility 
            Practically insoluble in water, slightly soluble in methanol, sparingly soluble in 
methylene chloride. It dissolves in 1 M sodium hydroxide.     
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pH         
         3-9 
pKa value 
          3.5, 4.1, 6.0 
Identification test 
          Melting point: 
                 261-263ºC 
        IR spectrum: 
                  Principle peak at wave number 3056.79, 2928.11, 1696.15, 758.33 cm-1 
show fig-2        
Storage 
           Stored at 25°C (77°F) in tightly closed containers in a cool and dry place 
Pharmacokinetics 
Absorption: 
            Oral administration, peak concentrations (Cmax) of telmisartan are reached in 
0.5-1 hour after dosing.  
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Distribution: 
               Food slightly reduces the bioavailability of telmisartan. The absolute 
bioavailability of telmisartan is dose dependent. At 40 and 160 mg the bioavailability 
was 42% and 58%, respectively. 
Excretion: 
             Eliminated unchanged in feces via biliary excretion; only minute amounts 
were found in the urine. 
Pharmacological action 
             Angiotensin II is the principle pressor agent of the renin-angiotensin system, 
with effects that include vasoconstriction, stimulation of synthesis and release of 
aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan 
blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by 
selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, 
such as vascular smooth muscle and the adrenal gland.  
Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the 
biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of 
hypertension 
Indications   
             Anti hypertension  
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Available Brand   
             Micardis 
                TELMA 
              TELSAR 
               TETAN    
Adverse effects 
             Upper respiratory tract infection, Back pain, Sinusitis, Diarrhea, Pharyngitis 
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2.2. REPORTED METHODS 
       2.2.1. METOPROLOL SUCCINATE: 
1. Vachhani kevin  H et al., (2011) 
“Development of validation of first order derivative spectrophotometric 
method for simultaneous estimation of Metoprolol succinate and olimesartan 
medoxomil in tablets”. 
      Method            - First order derivative spectrophotometric method  
                 Solvent            - Methanol 
                 λmax               -204.6nm,275.6nm 
2. Chandra Bose R.J.et al., (2011)  
“Validated Rp-Hplc meth0d for the simultaneous estimation of Ramipril and 
Metoprolol tartrate in Bulk and Tablet dosage form”. 
                 Elution                   - Isocratic 
                 Stationary phase    - Hypersil C18 column (150 mmx4.6 mm,5µm) 
               Mobile phase         -Acetonitrile: Methanol:10mM acetate buffer pH 5 
                                                     (30:50:20 v/v) 
                 Detection               - UV detector, 
                 Wavelength           -210nm 
3. Sagar B. Wankhede et al., (2011) 
“Stability indicating HPTLC method for quantitative determination of 
Atorvastatin calcium and Metoprolol succinate in capsules”. 
                Stationary phase - silica gel60 F254 (0.2 mm thickness) 
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                  Mobile phase      - Toluene: Methanol: Ethyl acetate: Glacial acetic acid   
                                                       7      :        1.5           :      1    :      0.5     (v/v) 
                Quantification     - Densitometry at 276 nm. 
                Wavelength           -254nm 
4.  Mitesh D et al., (2010)  
“Optimization and Establishment of a validated stability-indicating HPLC 
method for study of the stress degradation behavior of Metoprolol succinate”. 
                 Elution                  - Isocratic 
                 Stationary phase    - C-18 column 
                Mobile phase         -sodium dihydrogen phosphate buffer: Acetonitrile  
                                                     (70:30 v/v) 
                 Detection               - UV detector, 
                 Wavelength           -274nm 
5. Raja Kumar Seshadri et al., (2010) 
“Simultaneous Quantitative determination of Metoprolol, Atorvastatin and 
Ramipril in capsules by a validated stability-indicating RP-UPLC method”. 
                 Elution                  - Isocratic 
                 Stationary phase   - ZorbaxR XDC-C18 (4.6mmX50mm, 1.8µm) 
                Mobile phase       - Buffer:Acetonitrile (50:50 v/v) 
                  Detection              - UV detecter, 
                  Wavelength          -210nm 
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6. Rajendra Kakde  et al., (2009) 
“High performance thin layer chromatographic method for simultaneous 
estimation of Metoprolol succinate and amlodipine besylate in pharmaceutical 
preparations”. 
                 Stationary phase - silica gel60 F254 (0.2 mm thickness) 
                   Mobile phase - Methanol: Ethyl acetate: Water: Toluene: 25% Ammonia 
                                              1.5      :        5.0           :      0.3    :      3.0     :       0.3 (v/v) 
                 Quantification     - Densitometry at 236 nm. 
7. Moreshwar N. kulkarni  et al., (2009) 
“Development and validation of spectrophotometric method for determination 
of Metoprolol succinate”. 
      Method               - Maximum absorption  
                 Solvent               - Distilled water, phosphate buffer 6.8, 0.1M HCl 
                 λmax                     -224nm 
8. Mitesh D Phale  et al., (2009) 
“A validated and simplified RP-HPLC of Metoprolol succinate from bulk 
drugs”. 
                 Elution                  - Isocratic 
                 Stationary phase    - RP spherisorb C-18 (250 x4.6 mm. 10µm) 
                   Mobile phase        - Acetonitrile: methanol: 10mM aqueous phosphate                  
                                                                     buffer    
                                                     (20:20:60 v/v) 
                 Detection               - UV detecter. 
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9. Singh Brijesh et al., (2009) 
“Development of Reverse-phase HPLC method for simultaneous analysis of 
Metoprolol succinate and Hydrochlorothiazide in a tablet formulation”. 
                 Elution                  - Isocratic 
                 Stationary phase    - C-18 column 
                 Mobile phase         - 50mM di-sodium hydrogen phosphate: methanol: 
                                                      Acetonitrile 
                                                     (525:225:250 v/v) 
                 Detection               - UV detector, 
                 Wavelength           -222nm 
10. Senthamil selvan P. et al., (2008) 
“Chromatography-tandem mass spectrometry method for the simultaneous 
quantification of Metoprolol succinate and simuvastatin in human plasma”. 
                 Elution                  - Isocratic 
                 Stationary phase    - C-18 column 
                Mobile phase         - Acetonitrile: 0.5% formic acid PH 3.5  
                                                     (90:10 v/v) 
                 Detection               - Mass detector, 
                 Mode                      -positive 
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11. Sathe S.R  et al., (2008) 
“Development of HPTLC method for the estimation of Metoprolol succinate 
in bulk and          in tablet dosage form”. 
                 Stationary phase - silica gel60 F254 (0.2 mm thickness) 
                 Mobile phase      - Toluene: Methanol: Triethylamine 
                                                       3      :        0.5           :      0.3 
                 Quantification     - Densitometry at 274 nm. 
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2.2.2. TELMISARTAN 
1. Rekha Gangola  et al., (2011) 
“Spectrophotometric simultaneous determination of Hydrochlorothiazide and 
Telmisartan in combined dosage form”.  
      Method            - simultaneous equation  
                Solvent            - 0.1M NaoH 
                 λmax               -273nm,295nm 
2. Sagar Tatane et al., (2011) 
    “Development of UV spectrophotometric method of Telmisartan in Tablet 
formulation”. 
                Solvent            - Methanol: Water (70:30) 
                λmax               -230nm 
3. Rekha  Gangola et al., (2011) 
“Spectrophotometric simultaneous determination of Hydrochlorothiazide and 
Telmisartan in combined dosage form by dual wavelength method”. 
                Method            - Dual wavelength method.   
                Solvent            - 0.1M NaoH 
                λmax               -258nm,299nm,316nm,326nm 
4. Ilango K  et al., (2011) 
“Simultaneous estimation of Telmisartan and Hydrochlorothiazide in 
pharmaceutical dosage form”. 
      Method            - simultaneous equation  
                 Solvent            - Methanol 
                 λmax               - 296nm,270nm 
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5. Kumbhar S.T.   et al., (2011) 
 “Visible spectrophotometric determination of Telmisartan from urine”. 
Method            - colorimetric method 
                 Solvent            - Methanol 
                 Reagent           - Thionyl chloride 
                 λmax               -427nm 
6. Vijay kumar G et al., (2011) 
“Validated RP-HPLC method for the esatimation of Telmisatan in serum 
samples”. 
                 Elution                  - Isocratic 
                 Stationary phase    - Equsil (250X 4.6 mm, 5µ) 
                Mobile phase         - Buffer: Acetonitrile  
                                                     (35:65 v/v) 
                  Detection               - UV detector, 
                  Wavelength           - 282nm  
7. Patel Amit R et al., (2011) 
“Method development, validation and sability study for simultaneous 
estimation of Telmisartan and indapamide by Reverse phase-High 
performance liquid chromatography in pure and marked formulation”. 
                 Elution                  - Isocratic 
                 Stationary phase    - amazone C-18 (150X 4.6 mm, 5µ) 
                Mobile phase         - Buffer: Acetonitrile: Methanol  
                                                     (45:25:30v/v) 
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                 Detection               - UV detector, 
                 Wavelength           - 285nm 
8. Santaji Nalwade et al., (2011) 
“Rapid simultaneous determination of Telmisartan, Amlodipine besylate and 
Hydrochlorothiazide in combined poly pill dosage form by stability – 
indicating ultra performance liquid chromatography”. 
                 Elution                   - Isocratic 
                 Stationary phase    - C-18 (100X 2.1 mm, 1.7µ) 
               Mobile phase         - Sodium per chlorate buffer: Acetonitrile:  
                                                     (90:10v/v) 
                 Detection               - UV detector, 
     Wavelength           - 271nm, 237nm 
9. Ramesh J et al., (2011) 
 “Development and validation of HPTLC method for the simultaneous  
  estimation of Atorvastatin and Telmisartan in combined dosage form”. 
                  Stationary phase - silica gel60 F254 (10cm x 10 cm) 
                 Mobile phase      - Chloroform: Benzene: Methanol: Glacial acetic acid 
                                                      6      :        3           :      1.0          :        0.1   (v/v/v/v) 
                 Quantification     - Densitometer at 265 nm. 
10. Patel V.A et al., (2011) 
       “Development and validation of HPTLC method for the simultaneous   
        estimation of Telmisartan and Ramipril in combined dosage form”. 
                  Stationary phase - silica gel60 F254 (10 cm x 10 cm) 
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                  Mobile phase      - Acetone: Benzene: Ethyl acetate: Glacial acetic acid  
                                                       5.0      :        3.0           :      2    :      0.03     (v/v) 
                  Quantification     - Densitometry at 210 nm, 296 nm. 
11. Lakman V. Portale  et al., (2010) 
       “A validated stability indicting HPTLC method for simultaneous estimation of    
       Ramipril and Telmisartan”. 
                 Stationary phase - silica gel60 F254 (10 cm x 10 cm) 
                 Mobile phase      - Methanol: Chlorform 
                                                       1            :    6     (v/v) 
                 Quantification     - Densitometry at 210 nm. 
12. patil U.P et al., (2010) 
 “A validated densitometric method for analysis of Telmisartan and                            
Atorvastatin calcium in fixed dose combination”. 
                  Stationary phase - silica gel60 F254 (10 cm x 10 cm) 
                  Mobile phase      - Toluene: Methanol 
                                                       7           :    3     (v/v) 
                  Quantification     - Densitometry at 280 nm. 
13. Lakshmi  K.S. et al., (2010) 
“Stability indicating HPTLC method for simultaneous estimation of 
Telmisartan and Ramipril in tablets”. 
                  Stationary phase - silica gel60 F254 (10 cm x 10 cm) 
                  Mobile phase      - Toluene: Acetonitrile: Formic Acid: Water: 
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                                                       5          :    5                :   0.3             :     1    (v/v) 
                  Quantification     - Densitometry at 212 nm. 
14. Popat B. mohite  et al., (2010) 
 “Simultaneous estimation of Ramipril and Telmisartan in tablet dosage form   
  by spectrophotometry”. 
Method            - multicomponant method 
                 Solvent            - 0.2M H2SO4 
                 λmax               -205nm,291nm. 
15. Kalyankar T.M.  et al., (2010) 
“A rapid colorimetric method for the estimation of ammonia in Telmisartan in 
bulk and solid dosage form”. 
Method            - colorimetric method 
                 Solvent            - Water 
                 λmax               - 425nm. 
16. Vijayamirtharaj R. et al., (2010) 
       “Development and validation of RP-HPLC method for the simultaneous    
          estimation of Telmisartan of Atorvastatin calcium in tablet dosage forms”. 
                   Elution                   - Isocratic 
                   Stationary phase    - Phenomenex C-18 (250 X 4.6 mm, 5µ) 
                 Mobile phase         - Acetonitrile: Buffer (0.01M potassium dihydrogen           
                                                                                                     phosphate) 
                                                     (65:35v/v) 
                   Detection               - UV detector, 
Wavelength           - 250nm 
  49 
 
17. Yogesh Gupta et al., (2009)  
      “Isocratic RP-HPLC method development and validation for the simultaneous     
       estimation of Ramipril and Telmisartan in tablet dosage form”. 
                 Elution                   - Isocratic 
                 Stationary phase    - ODS column hypersil (250 X 4.6 mm, 5µ) 
                Mobile phase         - Acetonitrile: Buffer (3.9 gm sodium dihydrogen   
phosphate) 
                                                     (65:35v/v) 
                  Detection               - UV detector, 
Wavelength           - 210nm 
18. Wankhede SB et al., (2009) 
“RP-HPLC method for simultaneous estimation of Telmisartan and  
Hydrochlorothiazide in tablet dosage form”. 
                   Elution                   - Isocratic 
                   Stationary phase    - ODS column hypersil  C-18(25cm X 4.6 mm, 5µ) 
                  Mobile phase         - Acetonitrile: Buffer (0.05M Potassium dihydrogen  
phosphate 
(60:40v/v) 
                   Detection               - UV detector, 
       Wavelength           - 271nm 
 
 
  
 
 
 
 
 
 
 
 
3. AIM AND PLAN OF 
WORK 
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3.1 AIMOF WORK 
The prime importance of drug analysis is to gain information about the 
qualitative and quantitative composition of substance and chemical species, that is to 
find out what a substance is composed of and exactly how much. This information 
guides development of the manufacturing operations and therapeutic action of drugs.  
           Standard analytical procedure for newer drugs or its formulation may not be 
available in Pharmacopoeias. Hence it is essential to develop newer analytical 
methods which are accurate, precise, specific, linear, simple and rapid. 
           Metoprolol succinate and Telmisartan is a newer combination launched in 
Indian market. Metoprolol succinate and telmisartan drugs are used for treatment of 
hypertension. But there are several methods were reported for the estimation of 
metoprolol succinate and telmisartan individually as well as in combination with 
some other drugs. But there are no methods were reported for the estimation of these 
drugs in combined dosage forms without prior separation. 
            Hence the present study aims to develop simple, precise and accurate methods 
for the determination of metoprolol succinate and telmisartan by simple UV methods 
and RP-HPLC, HPTLC method in pure and tablet dosage form.  
3.2 PLAN OF WORK 
 The extensive survey of literature for metoprolol succinate and telmisartan 
regarding their physiochemical properties, pharmacological properties and 
analytical methods. This formed the basis for the development of methods. 
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 Selection and collection of metoprolol succinate and telmisartan working 
standard for analysis. 
 Identification of working standard by IR spectroscopy, Melting point tests. 
 Selection of suitable solvent for quantitative extraction of drug present in the 
tablet dosage form. The solvent should be readily available, economical and 
of analytical grade for UV-spectroscopy and HPLC grade for RP-HPLC and 
HPTLC should not chemically interact with the compound of interest and its 
structural characteristics. 
 Selection of suitable method for analysis depending upon the spectral 
characteristics of the drug. 
 Selection of suitable wavelength for rapid, accurate, precise and simple UV 
spectroscopic methods development. 
 Development of rapid and accurate RP-HPLC method by using UV detector. 
 Development of rapid and accurate HPTLC method by using UV detector. 
 Analysis of Tablet by the UV Spectroscopy and RP-HPLC, HPTLC Methods. 
 Statistical analysis of developed analytical methods. 
 Validation of analytical methods as per the ICH guidelines 
  
 
 
4. MATERIALS AND 
METHODS 
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4.1. MATERIALS USED 
4.1.1. DRUGS 
          Metoprolol succinate and Telmisartan were generously gifted by SKN 
Pharmaceuticals, Pondicherry and APEX Pharmaceuticals, Chennai. 
4.1.2. FORMULATION: 
 METOSARTAN-25 formulation, Sun-Pharma industries, containing 25 mg of 
Metoprolol succinate and 40 mg of Telmisartan was purchased from a local 
pharmacy. 
4.1.3. REAGENTS & CHEMICALS 
  All the chemicals used were of analytical reagent grade and HPLC grade 
procured from Qualigens, India Ltd.  The chemicals used for the study were 
Methanol (HPLC grade) 
Acetonitrile (HPLC grade) 
Water (HPLC grade) 
Chloroform (Analytical grade) 
            Methanol (Analytical grade) and 
Formic acid (Analytical grade) 
Hydrochloric acid (Analytical grade) 
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4.1.4. INSTRUMENTS SPECIFICATIONS 
1) Shimadzu AX – 200 digital balances: (Shimadzu instruction manual) 
Specifications 
Weighing capacity 200 gms 
Minimum display 0.1 mg 
Standard deviation ≤ 0.1 mg 
Operation temperature range  5 to 40° C 
2) Shimadzu UV – Visible spectrophotometer: (Shimadzu instruction manual) 
             Model : Shimadzu, UV-1700, Pharmaspec. Cuvetts: 1 cm matched quartz 
cells 
Specifications 
Light source 
20 W halogen lamp, Deuterium lamp. 
Light source position automatic adjustment. 
Mechanism 
Monochromator Aberration-correcting concave holographic grating 
Detector Silicon Photodiode 
Stray Light 
0.04% or less (220 nm: NaI 10 g L-1) 
0.04% or less (340 nm: NaNo2 50 g L-1) 
Measurement 190~1100 nm 
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wavelength range 
Spectral Band Width 1 nm or less (190 to 900 nm) 
Wavelength Accuracy ± 0.5 nm automatic wavelength calibration 
mechanism 
Recording range 
Absorbance : -3.99~3.99 Abs 
Transmittance : -399~399% 
Photometric Accuracy ± 0.004 Abs (at 1.0 Abs), ±0.002 Abs (at 0.5 Abs) 
Temperature/Humidity 
Temperature range : 15 to 35°C 
Humidity range : 35 to 80% (15 to below 30° C) 
   35 to 70% (30 to 35° C) 
 
3) High Performance Liquid Chromatography: (Water TM 486- Tunable absorbance 
detector) 
Detector Specifications 
Light source Deuterium Arc lamp 
Measurement wavelength 190 to 500 nm 
Spectral Band Width 5 nm 
Wavelength Accuracy ± 1 nm 
Cell path length 10 nm 
Cell volume  20 µ L-1 
Operating temperature range 4 to 35° C (39 to 104° F) 
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Recording range 0.0001 to 4.000 AUFS 
Operating 4 to 35° C / 75 % 
 
Pump Specifications-Water 510 HPLC pumps 
Pump type Double reciprocating plunger pump 
Pumping method Constant flow delivery and constant pressure 
delivery 
Suction filter 45 µm 
Line filter 5 µm mesh 
Operating 4 to 35° C (39 to 104° F) 
 
4)  High performance thin layer liquid chromatography: 
 Pre Coated Silica Gel Plates: 
Silica gel 60-254 aluminum sheets were procured from, Merck,     Drarm 
stadt,Germany. 
      CAMAG HPTLC System with Linomat 5 Applicator, 
      Camag TLC Scanner 3 and Wincats software 
 5) Sonica ultra sonic cleaner- model 2200 MH 
6) ELICO – pH meter model L1610 
7) Micropipette 
8) Melting point apparatus - Guna enterprises Chennai. 
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4.2 METHODS EMPLOYED  
The methods employed for the simultaneous estimation of Metoprolol 
succinate and Telmisartan are  
4.2.1. UV Spectrophotometric method 
a) Simultaneous Equation Method  
b) First order  derivative spectroscopic method   
c) Area under the curve method and 
d) Geometric correction method. 
Identification of Drugs 
Metoprolol succinate and Telmisartan working standards were identified from 
their Infra- Red spectrum shown in fig-1 & 2, melting point test shown in Table 3.  
Selection of solvent 
            The solubility of drugs were carried out using various polar to non polar 
solvents. The Solubility profiles of the drugs were determined as per the standards 
mentioned in the Indian Pharmacopoeia show in Table-1&2. The common solvent 
was found to be methanol and 0.1 M HCl. For the analysis of metoprolol succinate 
and telmisartan by the proposed method, 0.1 M HCl were chosen as solvent for 
Spectrophotometry, and it was selected on account of its ready availability, cost 
factor, solubility, and stability factor and cutoff
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Preparation of standard stock solution of Metoprolol succinate 
 Pure raw material of metoprolol succinate 10 mg was accurately weighed and 
dissolved in 0.1 M HCl to produce 1000 µg mL-1. From this 2 mL of the solution was 
transferred in to the 100 mL volumetric flask and made up to required volume with 
0.1 M HCl to get the concentration 20 µg mL-1.  It is used as a working standard. 
Preparation of standard stock solution of Telmisartan 
 Pure raw material of telmisartan 15 mg was accurately weighed and dissolved 
in 0.1 M HCl to produce 1000 µg mL-1. From this 2 mL of the solution was 
transferred in to the 50 mL volumetric flask and made up to required volume with 0.1 
M HCl to get the concentration 60 µg mL-1.  It is used as a working standard. 
Preparation of biological sample solution 
Pure raw material of metoprolol succinate 25 mg and telmisartan 40 mg was 
accurately weighed and dissolved in artificial urine to produce 1000 µg mL-1. From 
this 2 mL of the solution was transferred in to the 50 mL volumetric flask and made 
up to required volume with 0.1 M HCl to get the concentration 40µg mL-1, 60 µg mL-
1.  It is used as a working sample solution. 
Artificial urine preparation: 
                      To 1.5 liters of distilled water added 36.4 g of urea and mix until all the 
crystals were dissolved. Then added 15.0 g of sodium chloride, 9.0 g of potassium 
chloride and 9.6 g of sodium phosphate; mix until the solution was clear. Check the 
pH with indicator paper or a pH meter to ensure the pH is within the 5 to 7 pH range 
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for normal urine; if the solution is out of this pH range the pH may be lowered with 
1N hydrochloric acid or raised with 1N sodium hydroxide.  
Selection of wavelengths  
 The selection of wavelength for the estimation of metoprolol succinate and 
telmisartan, a suitable standard solution to contain 10 µg mL-1 of metoprolol 
succinate and telmisartan were prepared individually and scanned in the entire range 
from 200-400 nm. From the overlaid spectra, the two wavelengths 275nm for 
metoprolol succinate and 228.5nm telmisartan were selected for the construction 
simultaneous equation method. 
            For Derivative Spectroscopic method, the zero order spectrums were 
derivatised to their first order. In that 269 nm was selected for the estimation of 
metoprolol succinate, which is zero crossing for telmisartan and 243 nm, was selected 
for the estimation of telmisartan which is zero crossing for metoprolol succinate. 
            For Area under the curve method, the range of the areas were selected for both 
the drugs from their zero order spectra’s, 227.5-214 nm were chosen for the 
estimation of metoprolol succinate and 303-278.5 nm were chosen for the estimation 
of telmisartan. 
            For Geometric correction method, the three wavelengths were selected for 
both the drugs from their zero order spectra’s, 217,225,232 nm for the estimation of 
metoprolol succinate and 267,275,283 nm for the estimation of telmisartan. 
 
59 
 
Stability studies                     
            The stability studies were performed by measuring the absorbance of same 
solution at different time intervals. It was observed that metoprolol succinate and 
telmisartan in the specified solvent were stable for more than 4 hours at their 
wavelength maxima.  
Linearity 
            The linearity studies for the simultaneous equation method, Area under the 
curve method Geometric correction method, were performed at 275 nm, 227.5-
214nm, (217,225,232nm) and 228.5 nm, 303-278.5nm, (267,275,283nm) in the 
concentration range of 2-10 µg mL-1 for metoprolol succinate and 3.2-16 µg mL-1   for 
telmisartan.  
            For Derivative Spectroscopic method, the ∆A/∆λ values were measured in the 
first order derivative mode. Linearity was performed at 269 nm and 243 nm in the 
concentration range of 10-50 µg mL-1 for metoprolol succinate and 16-80 µg mL-1 
telmisartan. 
Preparation of calibration curve 
  The calibration curves were constructed by plotting absorbance Vs 
concentration for simultaneous equation method,  ∆A/∆λ Vs concentration for first 
order derivative method, Area Vs concentration for area under the curve method, 
Corrected absorbance Vs concentration for Geometric correction method.  
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Quantification of formulation 
Simultaneous equation method, Area under the curve method. 
                      Twenty tablets of (METOSARTAN-25) containing 25 mg Metoprolol 
succinate and 40 mg of Telmisartan) were weighed accurately. The average weight of 
tablets was found and powdered. The tablet powder equivalent to 25 mg of 
metoprolol succinate weighed and transferred  into 25 ml volumetric flask and added 
a minimum quantity of 0.1M HCl to dissolve the substance and made up to the 
volume with the same (1000 µg mL-1). The solution was sonicated for 15 minutes, 
centrifuged for 15 minutes at 100 rpm and filtered through Whatmann filter paper No. 
41. From the clear solution, further dilutions were made by diluting 4 mL of the 
solution was transferred into a 50 mL volumetric flask and made up to the required 
volume with 0.1M HCl to get the concentration 80 µg/ml. 0.5 mL were transferred 
into a series of 10 mL volumetric flasks and made up to the mark with 0.1M HCl to 
get the concentration of 4 µg mL-1 solution of metoprolol succinate which is also 
contains 6.4 µg/ml of telmisartan theoretically. The absorbance measurements were 
made six times for the formulations at 275 nm, 227.5-214 nm and 228.5 nm, and 303-
278.5 nm. The amount of metoprolol succinate and telmisartan were found by 
constructing Simultaneous equation method, for area under the curve method the area 
were substituted in the simultaneous equation to found the amount. 
For Derivative Spectroscopic Method: 
                       Twenty tablets of (METOSARTAN-25 containing 25 mg Metoprolol 
succinate and 40 mg of Telmisartan) were weighed accurately. The average weight of 
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tablets was found and powdered. The tablet powder equivalent to 25 mg of 
metoprolol succinate weighed and transferred  into 25 mL volumetric flask and added 
a minimum quantity of 0.1M HCl to dissolve the substance and made up to the 
volume with the same (1000 µg mL-1). The solution was sonicated for 15 minutes, 
centrifuged for 15 minutes at 100 rpm and filtered through Whatmann filter paper No. 
41. From the clear solution, further dilutions were made by diluting 20 mL of the 
solution was transferred into a 50 mL volumetric flask and made up to the required 
volume with 0.1M HCl to get the concentration 80 µg mL-1. 0.5 mL were transferred 
into a series of 10 mL volumetric flasks and made up to the mark with 0.1M HCl to 
get the concentration of 20 µg mL-1 solution of metoprolol succinate which is also 
contains 32 µg mL-1 of telmisartan theoretically. The ∆A/∆λ  measurements were 
made six times for the formulations at 269 nm and 243 nm. The amount of metoprolol 
succinate and telmisartan were found by constructing Area under curve method. 
For Geometric correction method: 
                          Twenty tablets of (METOSARTAN-25 containing 25 mg Metoprolol 
succinate and 40 mg of Telmisartan) were weighed accurately. The average weight of 
tablets was found and powdered. The tablet powder equivalent to 25 mg of 
metoprolol succinate weighed and transferred  into 25 mL volumetric flask and added 
a minimum quantity of artificial urine to dissolve the substance and made up to the 
volume with the same (1000 µg mL-1). The solution was sonicated for 15 minutes, 
centrifuged for 15 minutes at 100 rpm and filtered through Whatmann filter paper No. 
41. From the extracted solution, further dilutions were made by diluting 4 mL of the 
solution was transferred into a 50 mL volumetric flask and made up to the required 
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volume with 0.1M HCl to get the concentration 80 µg mL-1. 0.5 mL were transferred 
into a series of 10 mL volumetric flasks and made up to the mark with 0.1M HCl to 
get the concentration of 4 µg mL-1 solution of metoprolol succinate which is also 
contains 6.4 µg mL-1 of telmisartan theoretically. The absorbance measurements were 
made six times for the formulations at (217nm, 225nm, 232nm) and (267nm, 275nm, 
283nm). The same procedures were repeated without urine sample. Metoprolol 
succinate and telmisartan were found by constructing Geometric correction method 
and the amounts were found by substituted the corrected absorbance in the 
simultaneous equation method. 
Recovery studies  
                      The recovery experiment was done by adding known concentrations of 
metoprolol succinate and telmisartan working standard to the 50% pre analyzed 
formulations. Standard metoprolol succinate and telmisartan raw material solutions 
were prepared in 0.1 M HCl. Suitable amount of standard solutions containing 
concentrations of metoprolol succinate and telmisartan equivalent to 80 %, 100 % and 
120%  of  the test concentration  were added to the  50% pre analyzed formulation. 
The absorbances for simultaneous equation method, aera for area under curve 
method, ∆A/∆λ for derivative method, corrected absorbances for geometric 
correction method of the resulting solutions were measured at the selected 
wavelengths for the determination of metoprolol succinate and telmisartan for the 
four methods. The amount of each drug recovered was calculated. The procedure was 
repeated for three times.  
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Validation of developed method  
Linearity and Range 
From the calibration graphs plotted, metoprolol succinate and telmisartan 
shows the linearity between 2-10 µg mL-1, 3.2-16µg mL-1 for the Simultaneous 
equation, Geometric correction method and Area under Curve method, 10-50 µg mL-
1,
 16-80µg mL-1 for Derivative spectroscopic method respectively. 
Accuracy (Recovery studies)  
 Accuracy of the method was confirmed by recovery studies. The % RSD was 
calculated and tabulated. 
Precision 
            The repeatability of the method was confirmed by the analysis of tablets 
repeated for 6 times with the same concentration. The amount of each drug present in 
the tablets was calculated. The percentage RSD was calculated. The intermediate 
precision of the method was confirmed by intraday and interday analysis i.e. the 
analysis of tablets was repeated three times in the same day and on three successive 
days.  The amount of drugs was determined and the percentage RSD was calculated.     
Ruggedness  
 Ruggedness of the method was confirmed by the analysis of the tablets done 
by the different analysts. The amount and % RSD were calculated. 
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LOD and LOQ 
 The linearity study was carried out for six times. The LOD and LOQ were 
calculated by using the average of slope and standard deviation of response. 
4.2.2 RP-HPLC METHOD DEVELOPMENT AND OPTIMIZATION OF 
CHROMATOGRAPHIC CONDITIONS 
Selection of mobile phase 
Different mixtures of mobile phase with different ratios were selected and 
their chromatograms were recorded, they include the following 
         
          From the above information, in the mobile phase of Acetonitrile: Phosphate 
buffer pH 3 (25: 75 v/v), these two drugs were eluted with sharp peak and better 
resolution.  Hence this mobile phase was used.   
S.No Mobile phase Observation 
1  Acetonitrile: water (50: 50% v/v)  Telmisartan peak splited 
2 
Acetonitrile: Methanol: 
Water(60:30:10 v/v) 
No markable resolution between 
peaks 
3 
Acetonitrile : Methanol:  
Water(40:40:10  v/v) 
No markable resolution between 
peaks 
4 Acetonitrile : Buffer pH 5 Both peaks were not sharp. 
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Selection of Detection wavelength 
 Solutions of Metoprolol succinate and Telmisartan (10 µg mL-1) were 
prepared in the mobile phase and scanned in the UV region of 200 – 400 nm and 
recorded the spectrums. From the overlain spectra it was found that the two drugs 
have marked absorbance at 230 nm and can be effectively used for estimation of two 
drugs without interference. Therefore 230 nm was selected as detection wavelength 
for estimation of both the drugs by RP – HPLC method with an Isocratic elution 
technique. 
Stability of sample solutions  
 Solutions of Metoprolol succinate and Telmisartan (10 µg mL-1) were checked 
for their stability of absorbance at 230 nm and it was found that two drugs are stable 
for approximately 3 hour. 
Optimized chromatographic conditions 
 The following optimized conditions were employed for analysis of Metoprolol 
succinate and Telmisartan by Isocratic RP – HPLC method. 
Mode of operation -  Isocratic 
Stationary phase -   C18 column (250 mm × 4.6 mm i.d. 5µ) 
Mobile phase -  Acetonitrile: Phosphate buffer pH 3  
Proportion of mobile phase     - (25: 75 v/v)  
Detection wavelength    - 230 nm 
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Flow rate - 1.0 mL min-1 
Temperature - Ambient 
Sample load - 20 µL 
Operating pressure - 1000 psi 
Preparation of stock solution 
 Weighed accurately the tablet equivalent to 25 mg of metoprolol succinate  in 
a 25 mL volumetric flask and dissolved in methanol, after dissolution, the volume 
was made up to the mark with methanol. It contains 1000 µg mL-1 Metoprolol 
succinate and 1600 µg mL-1 of Telmisartan.   
Preparation of Calibration curve 
            From the stock solution, pipetted out 0.3mL, 0.4mL, 0.5mL, 0.6mL, and 
0.7mL of solutions to 5 separate 10 mL flasks and made up to the volume with 
mobile phase, solutions containing the concentrations of 30, 40, 50, 60, and 70 µg 
mL-1 of metoprolol succinate and 48, 64, 80, 96 and 112 µg mL-1 telmisartan. After 
acquiring study baseline, the solutions were injected and the chromatograms were 
recorded at 230 nm. The above concentration range was found to be linear and obeys 
Beer’s law. The procedure was repeated for six times. The peak areas were plotted 
against concentration and the calibration curve was constructed. 
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Estimation of Metoprolol succinate and Telmisartan in tablets 
 Estimation of metoprolol succinate and telmisartan in tablets by RP-HPLC 
was carried out using optimized chromatographic conditions. Weighed accurately the 
tablets  equivalent to 25 mg of metoprolol succinate  in a 10 mL volumetric flask and 
dissolved in methanol, after dissolve, the volume was made up to the mark with 
methanol. The content was sonicated for 15 minutes, and filtered through Whatmann 
filter paper No. 41. From the clear solution, 0.5 mL was transferred into six 10 ml (50 
µg mL-1 of metoprolol succinate  and 80 µg mL-1 of telmisartan ) volumetric flasks 
individually and made up to the mark with mobile phase. A steady base line was 
recorded with optimized chromatographic conditions. After the stabilization of base 
line for one hour, six test solutions of formulation were injected and recorded the 
chromatograms. The concentration of each test solution was determined by using 
slope and intercept values from the calibration graph. 
Recovery Experiments  
a) Preparation of Metoprolol succinate and Telmisartan  raw material stock 
solution 
 An accurately weighed quantity of 25 mg of metoprolol succinate and 40 mg 
of telmisartan were transferred into 25 mL volumetric flasks separately and added 
sufficient methanol to dissolve the substance and made up to the mark with the same 
solvent, it contains  metoprolol succinate   solution (50 µg mL-1) and telmisartan  
solution (80 µg mL-1). 
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Procedure 
To each 0.5 mL of preanalysed sample solution (50 µg mL-1 of Metoprolol 
succinate   and 80 µg mL-1 of Telmisartan), added 0.4 mL, 0.5 mL and 0.6 mL of 
metoprolol succinate   and telmisartan working standard stock solutions into 10 mL 
volumetric flasks and made up to the mark with mobile phase and performed the 
recovery as described under assay shown in fig -40 to 42. The quantity of drug 
recovered was calculated by using slope and intercept values from the calibration 
graph. 
System suitability studies 
            The system suitability parameters comply as per ICH guidelines and USP. The 
parameters like capacity factor, tailing factor, asymmetry factor, number of 
theoretical plate and resolution were calculated. 
4.2.3. HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY 
The various steps involved in HPTLC are 
♦ Selection of chromatographic layer 
♦ Sample and standard preparation 
♦ Layer pre-conditioning 
♦ Application of sample and standard 
♦ Chromatogram development 
♦ Detection of spots 
♦ Scanning 
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Instrument Specification Pre coated Silica Gel Plates  
 Silica gel 60-254 aluminum sheets were procured from, Merck, Drarm stadt, 
Germany. 
Stationary Phase 
                      Plate size(X x Y)                   - 20 x10 cm 
                     Material                              - Silica gel 60-254 aluminum sheets      
                     Pre washing                        -    No  
                     Modification                       -    No 
Instrument                                               
             CAMAG Automatic TLC sampler 4 (ATS4) with Linomat 5 
Applicator, CAMAG TLC Scanner 3 and Wincats software. 
CAMAG HPTLC System Chromatography Parameters 
                          Spray gas                            -         Nitrogen 
                          Sample solvent type           -        Methanol 
                          Dosage speed                     -          50 nL/s 
                          Pre dosage volume              -         0.2 µL 
Sequence  
                          Syringe size                         -       25 µL 
                          Application type                  -       Band 
                          Band length                         -        8 mm  
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Development – Glass Tank 
    Chamber type                -       Twin trough chamber 20 x10 cm 
                                                            Pre-conditioning                      
   Mobile phase                 -       Chloroform: Methanol: Formic acid 
                                                                 (85:15:2.5% v/v) 
   Solvent front position   -       50.0 mm 
   Volume                         -       10.0 mL 
   Drying device               -       Oven  
   Temperature                 -       60°C 
   Time                             -       5 minutes 
Detection  
                   CAMAG TLC Scanner 3 TLC scanner 3 
                     Display scaling      -      Automatic 
 Reagents and Chemicals 
 Chloroform  HPLC grade 
 Methanol gradient HPLC grade  
 Formic  acid HPLC grade  
 Silica gel 60 F254 aluminum sheets      
 Active pharmaceutical ingredients and formulation  
Optimized Chromatographic Conditions 
Sample prepared in                :    Methanol 
Stationary phase                    :    Silica gel 60 F254 aluminum sheets      
            Mobile phase                         :       Chloroform: Methanol: Formic acid 
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                                                                 (85:15:2.5% v/v)   
            Scanning wavelength            :     UV 233 nm  
            Development mode               :      Ascending mode 
Choice of Mobile Phase 
Initial trials were made with prepared TLC plates and pre- coated sheets, the 
spots were identified using shorter wavelength in UV chamber and they are 
confirmed by scanning in HPTLC scanner and the individual standards are also 
spotted to determine the Rf of each drugs. 
                 
The mobile phase chosen after trial was Chloroform: Methanol: Formic acid 
(85:15:2.5% v/v) due to its better resolution.  
Preparation of Standard Stock Solution 
 A standard stock solution of metoprolol succinate and telmisartan was 
prepared by dissolving in methanol and produced 1000 µgmL-1 and the solution was 
used to establish linearity 
 
TRIAL 
NO 
MOBILE PHASE RATIO 
1. Ethyl acetate: Methanol 80:20 
2. Ethyl acetate: Methanol : 10% Glacial acetic acid 80:20:1 
3. Ethyl acetate : n-Butanol : 10% Glacial acetic acid 60:20:20 
4. Toluene : Isopropyl alcohol :Water 50: 40:10 
5. Methanol : Chloroform 90:10 
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Sample Application  
   The sample was applied to the chromatographic plate and developed above 
said mobile phase, the volume, precision and exact positioning was ensured by the 
use of a suitable instrument and the plates were then air dried and placed into twin 
trough chamber for development of chromatogram.  
Chromatogram Evaluation 
 After development, the plates were dried using nitrogen gas and the different 
tracks in the chromatographic plate were scanned in a densitometer with a light beam 
of UV range. The absorbance was measured by reflectance. The peak area obtained 
and the Rf value was noted. 
Evaluation of Linearity 
From stock solution of 1000 µgmL-1, 1mL for metoprolol succinate, 1mL for 
telmisartan was pipette out in to a 50 mL volumetric flask and dissolved in methanol 
to get a concentration of 20 µgmL-1, 32 µgmL-1. From this, a final concentration of 
metoprolol succinate and telmisartan ranging from 1 µgmL-1 - 5 µgmL-1 and 1.6 
µgmL-1 – 8 µgmL-1 was obtained and this solution was spotted on a pre-coated TLC 
plates and developed as per the procedure discussed the peak area obtained for the 
different concentration. 
Calibration Graph 
A graph of peak area against concentration was constructed for metoprolol 
succinate and telmisartan in the concentration range of 1 µgmL-1 - 5 µgmL-1 and1.6 
µgmL-1 – 8 µgmL-1. It was found to be linear. 
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Quantification of formulation 
               Twenty tablets of each formulation (METOSARTAN-25) containing 25 mg 
of metoprolol succinate and 40 mg of telmisartan were accurately weighed and 
powdered. The powdered tablet equivalent to 25 mg metoprolol succinate and 40 mg 
of telmisartan   was transferred in to a 25 mL volumetric flask, added 20 mL of HPLC 
grade methanol and sonicated for 20 min, then shaken vigorously for few min and 
finally made up to the mark with HPLC methanol. The above solution was collected 
by filtering it through Whatmann filter paper No.41. From the filtered solution, 1mL 
to 50 mL volumetric flask and further diluted 1mL to 10 mL volumetric flask. From 
the solution 2 µgmL-1 spot was spotted on a Silica gel 60-F254 aluminum sheets are 
allowed to develop in Twin Trough Chamber 20 × 10 cm using Chloroform: 
Methanol: Formic acid (85:15:2.5% v/v) as a mobile phase, the solvent front position 
is noted, the plates are then removed and allowed it to dry in oven at 60˚C for 5 min. 
The spots are then detected using Camag TLC Scanner 3 and the peak area obtained 
at the detecting wave length 233 nm, the amount of metoprolol succinate and 
telmisartan was calculated using the linear regression equation. 
Recovery studies 
           The recovery experiment was done by adding known concentrations of 
metoprolol succinate and telmisartan working standard to the pre analyzed 
formulations. The results were determined. 
 
                                               
  
 
 
 
5. RESULTS AND 
DISCUSSION 
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5.1. RESULTS AND DICUSSION 
                    Simultaneous estimation of multiple drug formulations have advantage 
over the other methods, since it is less time consuming and less usage of solvent. Four 
simple, rapid, precise and accurate UV Spectroscopic methods, isocratic RP – HPLC 
method and HTPLC method were developed and validated for the estimation of 
Metoprolol succinate and Telmisartan in pure form, biological sample and in 
combined tablet dosage form. The methods employed are.  
1. UV Spectrophotoscopic methods 
i. Simultaneous Equation method 
ii. Derivative Spectrophotometric method 
iii. Area under the curve method 
iv. Geometric correction method 
2. RP – HPLC method 
3. HPTLC method 
5.1.1 UV SPECTROPHOTOSCOPIC METHODS: 
           The Metoprolol succinate and Telmisartan raw materials were identified by IR 
spectras shown in Figure 1 and 2. The solubility of Metoprolol succinate and 
Telmisartan was determined by Schefter and Higuchi method and as per Indian 
Pharmacopoeia. The polar and non-polar solvents were employed to dissolve the 
drugs. The solubility profile of Metoprolol succinate and Telmisartan was shown in 
Table 1 and 2. The Melting points were determined and shown in Table 3. 
 
75 
 
5. 1.1.1 SIMULTANEOUS EQUATION METHOD 
     The sample solutions of 10 µg mL-1 of metoprolol succinate and telmisartan 
in 0.1 M HCl prepared individually and the solutions were scanned in UV region in 
the wavelength range from 200 to 400 nm by using 0.1 M HCl as blank. The 
individual and overlaid spectrum of metoprolol succinate and telmisartan were 
recorded as shown in Figure 3 to 7. From the spectrum, 275 nm was chosen as the 
λmax of metoprolol succinate and 228.5 nm was chosen as the λmax of    telmisartan. 
The two wave lengths were applied for Simultaneous estimation of metoprolol 
succinate and telmisartan. 
            Aliquots of metoprolol succinate and telmisartan in 0.1 M HCl was prepared 
in the concentration range of 2-10 µg mL-1 and 3.2-16µg mL-1. The absorbances of 
solutions were measured at selected wavelengths for metoprolol succinate and 
telmisartan respectively. The calibration curve was plotted using concentration 
against absorbance.  The calibration curve was plotted and shown in Figure 8 to 11. 
The procedure was repeated six times for each drug at their selective wavelengths. 
The optical parameters like, Sandell’s sensitivity, Molar absorptivity, correlation 
coefficient, slope, intercept, LOD, LOQ and Standard error were calculated. The 
correlation coefficient for all the two drugs was found to be around 0.999. This 
indicates that both the drugs obey Beer’s law and they were linear at the selected 
concentration range. The optical characteristics of two drugs at their selected 
wavelengths were shown in Table 4&5.  
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         For Quantification, the concentration of solution containing 4 µg mL-1 of 
metoprolol succinate and 6.4 µg mL-1 telmisartan was prepared and measured at their 
respective wavelengths. The percentage purity of tablets was found to be 100.76 ± 
1.2076 and 100.78 ± 0.1649 for metoprolol succinate and telmisartan respectively. 
The amount present in tablets was in good concord with the label claim and the % 
RSD values were found to be 1.1986 and 0.1637 for metoprolol succinate and 
telmisartan, respectively. The low % RSD value indicates that the method has good 
precision. The results of analysis are shown in Table 6. 
         Further, the precision of the method was confirmed by Intraday and Inter day 
analysis. The analysis of the formulation was carried out for three times in the same 
day and one time in the three consecutive days. The % RSD value of intraday and 
inter day analysis were found to be 0.8852 and 0.8663 for metoprolol succinate, 
0.3010 and 0.3011 for telmisartan. The results of analysis are shown in Table 7. The 
results showed that the precision of the method was confirmed. 
 The developed method was validated for Ruggedness. It refers to the 
specificity of one lab to multiple lab which may include different analysts and 
different sources of reagents and so on. In the present work it was confirmed by 
different analysts. The % RSD value of 80%, 100%, 120% by analyst 1 and analyst 2 
were found to be 0.6080, 0.4330, 0.6392 and 0.1698, 0.9876, 0.3637 for metoprolol 
succinate and 0.1142, 1.0897, 0. 1309 and 0.1085, 0.6206, 0.2777 for telmisartan, 
respectively. The low % RSD values indicate that the developed method was more 
rugged. The results were shown in Table 8. 
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         The accuracy of the method was performed by recovery studies. To the 50% 
preanalysed formulations, a known quantity of metoprolol succinate and telmisartan 
raw material solutions were added at three different concentrations. The absorbance 
of the solutions was measured and the percentage recovery was calculated. The 
percentage recovery was found to be in the range of 99.91 ± 0.3579 for metoprolol 
succinate and 101.28 ± 0.2419 for telmisartan. The average % RSD values of 
metoprolol succinate and telmisartan were found to be 0.3582 and 0.2392, 
respectively. The low % RSD value for drugs indicates that this method is very 
accurate. The recovery data is shown in Table 9. 
5.1.1.2 AREA UNDER THE CURVE METHOD 
            The solutions containing 10 µg mL-1 of metoprolol succinate and telmisartan 
in 0.1 M HCl were prepared individually and the solutions were scanned in UV 
region in the wavelength range from 200 to 400 nm by using 0.1M HCl as blank. 
From the spectrum, 227.5-214 nm was chosen as the area range for metoprolol 
succinate and 303-278.5 nm was chosen as the area range for telmisartan. This two 
wave length ranges were used for the estimation of metoprolol succinate and 
telmisartan by area under the curve method. 
            Aliquots of Metoprolol succinate and Telmisartan in 0.1 M HCl was prepared 
in the concentration range of 2-10 µg mL-1 and 3.2-16µg mL-1. The area of the 
solutions was measured at selected wavelengths for metoprolol succinate and 
telmisartan respectively. The calibration curve was plotted using area against 
concentration. The calibration graphs were plotted and are shown in Figure 12 to 15. 
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The preparation of calibration curve was repeated for six times for each drug at their 
selective wavelengths. The optical parameters like, Sandell’s sensitivity, Molar 
absorptivity, correlation coefficient, slope, intercept, LOD, LOQ and Standard error 
were calculated. The correlation coefficient for both the drugs was found to be around 
0.999. This indicates that both the drugs obey Beer’s law and they were linear at the 
selected concentration range. The optical characteristics of two drugs at their selective 
wavelengths are shown in   Table 10&11.  
        The concentration of solution containing 4 µg mL-1 of metoprolol succinate and 
6.4 µg mL-1    of telmisartan was prepared and the area of the solutions was measured 
at their respective wavelength ranges. The percentage purity of tablets was found to 
be 99.71 ± 0.6881 and 99.82 ± 0.3045 for metoprolol succinate and telmisartan, 
respectively. The amount present in tablets was in good concord with the label claim 
and the % RSD values were found to be 0.6901 and 0.3051 for metoprolol succinate 
and telmisartan, respectively. The results of analysis were shown in Table 12. The 
low % RSD value indicates that the method was highly precise.  
.        Further, the precision of the method was confirmed by Intraday and Inter day 
analysis. The analysis of formulation was carried out for three times in the same day 
and one time in the three consecutive days. The % RSD value of intraday and inter 
day analysis were found to be 1.4717 and 1.4801 for metoprolol succinate, 0.0301 
and 0.0301 for telmisartan. The results of analysis are shown in Table 13. The results 
revealed that the method was highly precise. 
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 The developed method was validated for Ruggedness. It refers to the 
specificity of one lab to multiple lab which may include different analysts, different 
sources of reagents and so on. In the present work it was confirmed by different 
analysts. The % RSD value 80%, 100%, 120% by analyst 1 and analyst 2 was found 
to be 0.3575, 1.4515, 0.8402 and 0.4027, 0.4276, 0.2019 for metoprolol succinate and 
0.0348, 0.4640, 0.1995 and 0.0.6038, 0.0870, 0.7029 for telmisartan, respectively. 
The low % RSD value indicates that the developed method was more rugged. The 
results were shown in Table 14. 
            The accuracy of the method was performed by recovery studies. To the 50% 
preanalysed formulations, a known quantity of metoprolol succinate and telmisartan 
raw material solutions were added at three different concentration levels. The 
absorbance of the solutions was measured and the percentage recovery was 
calculated. The percentage recovery was found to be in the range of 101.34 ± 1.4893 
for metoprolol succinate and 99.33 ± 0.2205 for telmisartan. The average %RSD 
values of metoprolol succinate and telmisartan was found to be 1.4697 and 0.2220, 
respectively. The low % RSD value of drugs indicates that this method was accurate. 
The recovery data is shown in Table 15.  
5.1.1.3 DERIVATIVE SPECTROPHOTOMETRIC METHOD 
The zero order spectrums were derivatised into first order derivative 
spectrums. The individual and overlaid first order derivative spectrum of metoprolol 
succinate and telmisartan was recorded as shown in Figure 16 to 18. From the 
spectrum, 269 nm was selected for the estimation of metoprolol succinate, which is 
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zero crossing for telmisartan and 243 nm was selected for the estimation of 
telmisartan which is zero crossing for metoprolol succinate. Aliquots of metoprolol 
succinate and telmisartan were prepared in the concentration range of 10-50 µg mL-1 
and 16-80µg mL-1. The ∆A/∆λ value of these solutions was measured at 269 nm and 
243 nm in the first order derivative spectrum for metoprolol succinate and 
telmisartan, respectively. The plotted calibration curves were shown in Figure 19 & 
20 for metoprolol succinate and telmisartan, respectively. The preparation of 
calibration curve was repeated for six times for each drug at their selective 
wavelength. The calibration curve was plotted using concentration against ∆A/∆λ. 
The optical parameters like, Sandell’s sensitivity, Molar absorptivity, correlation 
coefficient, slope, intercept, LOD, LOQ and Standard error were calculated for both 
the drugs. The correlation coefficient for all the two drugs was found to be above 
0.999. This indicates that both the drugs obey Beer’s law and they were linear at the 
selected concentration range. The results are shown in Table16.  
 For Quantification, the concentration of solution containing 20 µg mL-1 of 
metoprolol succinate and 32 µg mL-1 of telmisartan was prepared and measured at 
their respective wavelengths.  The amount of six test solutions was determined. The 
percentage purity of granules was found to be 101.01 ± 1.3426 and 101.19 ± 1.0604 
for metoprolol succinate and telmisartan, respectively. The amount present in tablets 
was in good concord with the label claim and the % RSD values were found to be 
1.3291 and 1.0479 for metoprolol succinate and telmisartan, respectively. The results 
of analysis are shown in Table-17. The low % RSD value indicates that the method 
has good precision.  
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Further, the precision of the method was confirmed by Intraday and Inter day 
analysis. The analysis of tablets was carried out for three times in the same day and 
one time in the three consecutive days. The % RSD value of Intraday and Inter day 
analysis are 0.4038 and 0.3165 for metoprolol succinate, 0.3187 and 0.2676 for 
telmisartan, respectively. The results of analysis are shown in Table 18. Hence the 
precision was confirmed.  
            The developed method was validated for Ruggedness. It refers to the 
specificity of one lab to multiple lab which may include different analysts, different 
instruments and different sources of reagents and so on. In the present work, it was 
confirmed by different analysts. The % RSD value of 80%, 100%, 120% by analyst 1 
and analyst 2 were found to be 1.7413, 1.4707, 1.2164 and 1.3019, 1.4707, 1.2164 for 
metoprolol succinate and 0.4357, 1.4797, 0.2582 and 0.1755, 0.3829, 0.1293 for 
telmisartan, respectively. The low % RSD value indicates that the developed method 
was more rugged. The results are shown in Table 19. 
 The accuracy of the method was performed by recovery studies. To the 50% 
preanalysed formulations, a known quantity of metoprolol succinate and telmisartan 
raw material solutions were added at three different concentration levels. The 
absorbance of the solutions was measured and the percentage recovery was 
calculated. The percentage recovery was found to be in the range of 100.72 ± 0.6862 
for metoprolol succinate, and 100.42 ± 0.4465 for telmisartan. The average %RSD 
values of metoprolol succinate and telmisartan was found to be 0.6813 and 0.4446, 
respectively. The low % RSD values of the drugs reveals that the method was more 
accurate. The recovery data was shown in Table 20.  
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5.1.1.4 GEOMETRIC CORRECTION METHOD: 
                   In the geometrical correction, the corrected absorbance were 
obtained above said equation for both the drugs was solved by using simultaneous 
equation method which is simple, accurate, precise and used for quantitative 
simultaneous estimation of MET and TEL in biological sample. 
                 The solutions containing 10 µg mL-1 of metoprolol succinate and 
telmisartan in 0.1 M HCl were prepared individually and the solutions were scanned 
in UV region in the wavelength range from 200 to 400 nm by using 0.1 M HCl as 
blank. From the spectrum, 217nm, 225nm, 232 nm was chosen as the wavelengths for 
Metoprolol succinate and 267nm, 275nm, 283nm was chosen as the wavelengths for 
Telmisartan. This six wave length ranges were used for the estimation of metoprolol 
succinate and telmisartan by geometric correction method shown in Figure- 21 to 23. 
            Aliquots of metoprolol succinate and telmisartan in 0.1 M HCl was prepared 
in the concentration range of 2-10 µg mL-1 and 3.2-16µg mL-1. The absorbance of the 
solutions was measured at 217nm, 225nm, 232nm for metoprolol succinate. The 
calibration curve was plotted using area against concentration. The calibration graph 
at 217nm, 225nm, 232nm was shown in Figure 24 to 27. The area of telmisartan 
solutions were measured at 267nm, 275nm, 283 nm. The calibration graphs were 
plotted and are shown in Figure 25. The preparation of calibration curve was repeated 
for six times for each drug at their selective wavelengths. The optical parameters like, 
Sandell’s sensitivity, Molar absorptivity, correlation coefficient, slope, intercept, 
LOD, LOQ and Standard error were calculated. The correlation coefficient for both 
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the drugs was found to be around 0.99. This indicates that both the drugs obey Beer’s 
law and they were linear at the selected concentration range. The optical 
characteristics of two drugs at their selective wavelengths are shown in   Table 
21&22.  
        The concentration of solution containing 4 µg mL-1 of metoprolol succinate and 
6.4 µg mL-1    of telmisartan were prepared and the absorbance of the solutions was 
measured at their respective wavelength ranges. The percentage purity of Tablets was 
found to be 100.00 ± 0.3019 and 100.17 ± 0.3058 for metoprolol succinate and 
telmisartan, respectively. The amount present in tablets was in good concord with the 
label claim and the % RSD values were found to be 0.3018 and 0.3052 for metoprolol 
succinate and telmisartan, respectively. The results of analysis were shown in Table 
23. The low % RSD value indicates that the method was highly precise. .         
            The accuracy of the method was performed by recovery studies. To the 50% 
preanalysed formulations, a known quantity of metoprolol succinate and telmisartan 
raw material solutions were added at three different concentration levels. The 
absorbance of the solutions was measured and the percentage recovery was 
calculated. The percentage recovery was found to be in the range of 99.88 ± 0.5521 
for metoprolol succinate and 100.14 ± 0.2145 for telmisartan. The average %RSD 
values of metoprolol succinate and telmisartan was found to be 0.5528 and 0.2142, 
respectively. The low % RSD value of drugs indicates that this method was accurate. 
The recovery data is shown in Table 24.  
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5.1.2 RP – HPLC METHOD 
    A simple, rapid, accurate and precise method for the estimation of 
metoprolol succinate and telmisartan in pure and in tablet dosage form by an isocratic 
RP – HPLC method. 
  The solutions of 10 µg mL-1 of metoprolol succinate and telmisartan in 
mobile phase Acetonitrile: Phosphate buffer pH 3 (25:75 v/v) were prepared and the 
solutions were scanned in the range of 200 – 400 nm. It was found that all two drugs 
have marked absorbance at 230 nm and can be effectively used for estimation of two 
drugs without interference. The selection of detection wavelength was shown in 
Figure 28. Therefore 230 nm was selected as detection wavelength for estimation of 
two drugs by RP – HPLC method with an isocratic elution technique and it was found 
that two drugs are stable for approximately 24 hours. 
              The optimization was done by changing the composition of mobile phase, 
ratio and pH. After calculating all system suitability parameters, Acetonitrile: 
Phosphate buffer pH 3 with the ratio of 25:75 v/v at a flow rate of 1.0 ml min-1 was 
selected and the optimized chromatogram was shown in Figure 23. The retention time 
of metoprolol succinate and telmisartan were found to be 2.45 and 6.99, respectively. 
The retention time between two drugs indicates that the drugs were separated with 
better resolution of 4.5 between metoprolol succinate and telmisartan. The system 
suitability parameters for the optimized chromatogram are shown in Table 25. 
 With the optimized chromatographic conditions, stock solutions containing 
metoprolol succinate and telmisartan 10 µg mL-1 were prepared in mobile phase. The 
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stock solution was further diluted to concentration range of   30-70 µg mL-1 of 
metoprolol, 48-112 µg mL-1 of telmisartan.  20 µL of each solution was injected and 
recorded the chromatograms at 230 nm. The chromatograms were shown in Figure 29 
to 33. The calibration curve was plotted using concentration against peak area. The 
procedure was repeated for six times. The correlation co-efficient was found to be 
around 0.999 for both the drugs. The calibration graph of Metoprolol succinate and 
Telmisartan was shown in Figure 34 and 35, respectively. The optical characteristics 
of metoprolol succinate and telmisartan were shown in Table 26. 
 The six test concentration containing 50 µg mL-1 metoprolol succinate and 80 
µg mL-1 telmisartan was prepared from formulation. 20 µL of each solution was 
injected and chromatograms were recorded. The percentage purity was found to be 
100.02 ± 0.4736 and 99.33 ± 0.3189 for metoprolol succinate and telmisartan, 
respectively. The precision of the method was confirmed by repeatability of 
formulation for six times and the chromatograms were shown in Figure 36 to 41. The 
percentage RSD was found to be 0.4734 and 0.3211 for metoprolol succinate and 
telmisartan, respectively. It indicates that the method has good precision. The data is 
shown in    Table 27. 
 The accuracy of the method was performed by recovery studies. To the 100% 
preanalyzed formulations, a known quantity of metoprolol succinate and telmisartan 
raw material solutions were added at three different concentration levels. The 
chromatograms were recorded as shown in the Figure 42 to 44. The percentage 
recovery was found to be in the range between 101.92 and 103.53% for metoprolol 
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succinate and 98.93 and 100.05% for telmisartan. The average %RSD values of 
metoprolol succinate and telmisartan was found to be 0.8933 and 0.5763, 
respectively. The low % RSD values for recovery indicated that the method was 
accurate. The values are given in the Table 28. The high percentage recovery revealed 
that no interference produced due to the excipients used in tablets. Therefore, the 
developed method was found to be more accurate. All the above parameters with the 
ease of operation ensure that the projected methods could be applied for the routine 
analysis of metoprolol succinate and telmisartan in pure form and in tablet dosage 
forms. 
5.1.3 HIGH PERFORMANCE THIN LAYER LIGUID CHROMATOGRAPHY  
            A simple, rapid, accurate and precise method for the estimation of Metoprolol 
succinate and Telmisartan in pure and in tablet dosage form by HPTLC method. 
              The solutions of 10 µg mL-1 of metoprolol succinate and telmisartan in 
mobile phase Chloroform: Methanol: Formic acid in the ratio of (85: 15: 2.5%v/v) 
were prepared and the solutions were scanned in the range of 200 – 400 nm. It was 
found that all two drugs have marked absorbance at 233 nm and can be effectively 
used for estimation of two drugs without interference. The selection of detection 
wavelength was shown in Figure 45. Therefore 233 nm was selected as detection 
wavelength for estimation of two drugs by HPTLC method and it was found that two 
drugs are stable for approximately 3 hours. 
                Various mobile phase systems were prepared and trials were made with 
pre-coated plates to determine appropriate chromatographic conditions. The mobile 
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phase finalized for HPTLC analysis was Chloroform: Methanol: Formic acid in the 
ratio of (85: 15: 2.5%v/v) and the chromatogram was developed. The Rf value of 
metoprolol succinate and telmisartan were found to be 0.45 and 0.58, respectively. 
The scanning of the developed plates shows a good peak shape. 
  The Linearity of HPTLC method developed for metoprolol succinate and 
telmisartan was evaluated by injecting the standard drug solutions of different 
concentration ranging from 1 – 5 µg mL-1 and 1.6 -8 µg mL-1 chromatogram were 
shown in Figure 46 to 50 and the peak areas obtained spectrum of metoprolol 
succinate and telmisartan in all the tracks are presented in Figure 51. The calibration 
curve was plotted using concentration against peak area. The procedure was repeated 
for six times. The correlation co-efficient was found to be around 0.999 for both the 
drugs. The calibration graph of metoprolol succinate and telmisartan was shown in 
Figure 52 and 53, respectively. 
The various optical parameters like Regression equation, Slope, Intercept, LOD, 
LOQ, Sandell’s sensitivity, standard error were calculated and the results are presented in 
Table 29. 
The Assay determined the contents of metoprolol succinate and telmisartan 
formulation METOSARTAN-25 were found to be 100.89 ± 0.4755 and 100.55 ± 0.5606. 
The precision of the method was confirmed by repeatability of formulation for six times 
and the chromatograms were shown in Figure 54 to 59. The Assay results presented in the 
Table 30. 
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  The Accuracy and Precision was determined for metoprolol succinate and 
telmisartan by fortifying sample with standard drug substance at overall recovery 
determined, the contents of METOSARTAN-25 the percentage recovery was found to be 
100.61% for metoprolol succinate, and 100.81% for telmisartan. The chromatograms were 
recorded as shown in the Figure 60 to 62. The % RSD values were found to be 0.9053 and 
0.7429 for metoprolol succinate and telmisartan respectively. The low % RSD value for 
both drugs indicates that this method is very accurate.      
The proposed HPTLC method for estimation of metoprolol succinate and telmisartan 
in tablet dosage form is simple, accurate and rapid. The statistical parameters in the 
method validation studies for Precision and Accuracy with no interference, which was 
proved by recovery studies, the data presented in the Table 31. Difference between 
shorter and longer wavelength of metoprolol succinate and telmisartan were recorded 
as shown in Figure 63. 
 
 
  
 
 
6. SUMMARY 
AND 
CONCLUSION 
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SUMMARY AND CONCLUSION 
Metoprolol succinate and Telmisartan drugs are used for the treatment of 
hypertension. Simple, rapid, precise and accurate UV Spectroscopic method, RP – 
HPLC AND HPTLC method were developed and validated for the estimation of 
metoprolol succinate and telmisartan in pure, pharmaceutical dosage form and 
biological sample.  
6.1 UV Spectroscopic method 
 From the solubility data, 0.1 M HCl was selected as the solvent. Metoprolol 
succinate and telmisartan (10 µg mL-1) solution were prepared separately and scanned 
in UV region. From overlaid spectrum, 275 nm and 228.5 nm were selected for 
detection wavelength for Simultaneous Equation method. The percentage purity 
present in tablets was found to be 100.76 ± 1.2076 and 100.78 ± 0.1649 for 
metoprolol succinate and telmisartan respectively. The percentage recovery was 
found to be in the range of 99.91 ± 0.3579 for metoprolol succinate and 101.28 ± 
0.2419 for telmisartan. 
            In area under the curve method, the wavelength ranges 227.5-214 nm and 
303-278.5 nm were selected for the estimation of metoprolol succinate and 
telmisartan respectively. The percentage label claim present in tablets was found to be 
99.71 ± 0.6881 and 99.82 ± 0.3045 for metoprolol succinate and telmisartan, 
respectively. The percentage recovery was found to be in the range of 101.34 ± 
1.4893 for metoprolol succinate and 99.33 ± 0.2205 for telmisartan  
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 The same spectrum were derivatised and from overlaid spectrum 269 nm 
selected for detection of metoprolol succinate where telmisartan shows zero crossing 
and also 243 nm selected for detection of telmisartan where metoprolol succinate 
show zero crossing. The percentage label claim present in tablets was found to be 
101.01 ± 1.3426 and 101.19 ± 1.0604 for metoprolol succinate and telmisartan, 
respectively. The percentage recovery was found to be in the range of 100.72 ± 
0.6862 for metoprolol succinate, and 100.42 ± 0.4465 for telmisartan.. 
         In the geometrical correction, the corrected absorbance was obtained above said 
equation for both the drugs were solved by using simultaneous equation method. The 
wavelength ranges 217 nm, 225 nm, 232 nm and 267 nm, 275 nm, 283 nm were 
selected for the estimation of metoprolol succinate and telmisartan respectively. The 
percentage label claim present in tablets was found to be 100.00 ± 0.3019 and 100.17 
± 0.3058 for metoprolol succinate and telmisartan, respectively. The percentage 
recovery was found to be in the range of 99.88 ± 0.5521 for metoprolol succinate and 
100.14 ± 0.2145 for telmisartan.  
6.2 RP – HPLC METHOD 
In RP-HPLC method, the mobile phase used is Acetonitrile: Phosphate buffer 
pH 3 (25:75 v/v) with flow rate of 1 mL per minute, the retention time of metoprolol 
succinate and telmisartan were found to be 2.45 and 6.99, respectively at 230 nm.  
 The percentage purity was found to be 100.02 ± 0.4736 and 99.33 ± 0.3189 
for metoprolol succinate and telmisartan respectively. The precision of the method 
was confirmed by repeatability of formulation for six times. The accuracy of the 
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method was confirmed by recovery studies. The percentage recovery was found to be 
in the range between 101.92 and 103.53% for metoprolol succinate and 98.93 and 
100.05% for telmisartan. The low % RSD values for recovery indicated that the 
method was accurate.  
6.3 HIGH PERFORMANCE THIN LAYER LIGUID CHROMATOGRAPHY 
In HPTLC method, the mobile phase used is Chloroform: Methanol: Formic 
acid in the ratio of (85: 15: 2.5%v/v) and the chromatogram was developed. The Rf 
value of metoprolol succinate and telmisartan were found to be 0.45 and 0.58, 
respectively at 232 nm. The scanning of the developed plates shows a good peak 
shape.  
 The percentage purity was found to be 100.89 ± 0.4755 and 100.55 ± 0. for 
metoprolol succinate and telmisartan respectively. The precision of the method was 
confirmed by repeatability of formulation for six times. The accuracy of the method 
was confirmed by recovery studies. The percentage recovery was found to be in the 
range between 100.61% for metoprolol succinate, and 100.81% for telmisartan. The 
low % RSD values for recovery indicated that the method was accurate.  
  Simple, rapid and accurate UV Spectroscopic (Simultaneous Equation 
method, First order derivative method, Area under the curve method and Geometric 
correction method ) and an isocratic RP - HPLC and HPTLC methods showed 
excellent sensitivity, reproducibility, accuracy and repeatability, which is evidenced 
by low percentage relative standard deviation.  The results obtained in recovery 
studies were indicating that there is no interference from the excipients used in the 
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formulation. Hence it is suggested that the proposed UV Spectroscopic, an isocratic 
RP – HPLC and HPTLC methods can be effectively applied for the routine analysis 
of metoprolol succinate and telmisartan in bulk, biological sample and in tablet 
formulation and the obtained results will be presented elsewhere.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
7.FIGURES 
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FIGURE-1 
IR SPECTRUM OF METOPROLOL SUCCINATE 
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FIGURE-2 
IR SPECTRUM OF TELMISARTAN 
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FIGURE-3 
UV SPECTRUM OF METOPROLOL SUCCINATE IN 0.1M HCL AT 222 nm 
(MAXIMUM ABSORPTION) 
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FIGURE-4 
UV SPECTRUM OF TELMISARTAN IN 0.1M HCL AT 291 nm 
(MAXIMUM ABSORPTION) 
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FIGURE-5 
UV SPECTRUM OF METOPROLOL SUCCINATE IN 0.1M HCL AT 275 nm 
(SIMLTANEOUS EQUATION METHOD) 
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FIGURE-6 
UV SPECTRUM OF TELMISARTAN IN 0.1M HCL AT 228.5 nm 
(SIMLTANEOUS EQUATION METHOD) 
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FIGURE-7 
OVERLAID SPECTRA OF METOPROLOL SUCCINATE AND TELMISARTAN 
(SIMULTANEOUS EQUATION) 
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FIGURE-8 
CALIBRATION CURVE FOR METOPROLOL SUCCINATE IN 0.1M HCL AT 
275 nm 
(SIMULTANEOUS EQUATION METHOD) 
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FIGURE-9 
CALIBRATION CURVE FOR METOPROLOL SUCCINATE IN 0.1M HCL AT 
228.5nm 
(SIMULTANEOUS EQUATION METHOD) 
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FIGURE-10 
CALIBRATION CURVE FOR TELMISARTAN IN 0.1M HCL AT 228.5 nm 
(SIMULTANEOUS EQUATION METHOD) 
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FIGURE-11 
CALIBRATION CURVE FOR TELMISARTAN IN 0.1M HCL AT 275 nm 
(SIMULTANEOUS EQUATION METHOD) 
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FIGURE-12 
CALIBRATION CURVE FOR METOPROLOL SUCCINATE AT 227.5-214 nm 
(AREA UNDER CURVEMETHOD) 
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FIGURE-13 
CALIBRATION CURVE FOR METOPROLOL SUCCINATE AT 303-278.5nm  
(AREA UNDER CURVEMETHOD) 
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FIGURE-14 
CALIBRATION CURVE FOR TELMISARTAN AT 303- 278.5 nm 
(AREA UNDER METHOD) 
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FIGURE-15 
CALIBRATION CURVE FOR TELMISARTAN AT 227.5-214 nm 
(AREA UNDER METHOD) 
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FIGURE-16 
FIRST ORDER DERIVATIVE SPECTRUM OF METOPROLOL SUCCINATE 
IN 0.1M HCL AT 269 nm 
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FIGURE-17 
FIRST ORDER DERIVATIVE SPECTRUM OF TELMISARTAN  
IN 0.1M HCL AT 243 nm 
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FIGURE-18 
OVERLAID SPECTRUM OF FIRST ORDER DERIVATIVE OF 
METOPROLOLSUCCINATE AND TELMISARTAN IN 0.1M HCL 
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FIGURE-19 
CALIBRATION CURVE FOR METOPROLOL SUCCINATE AT 269 nm 
(FIRST ORDER DERIVATIVE SPECTROSCOPIC METHOD) 
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FIGURE-20 
CALIBRATION CURVE FOR TELMISARTAN AT 243 nm 
 (FIRST ORDER DERIVATIVE SPECTROSCOPIC METHOD)  
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FIGURE-21 
OVERLAID SPECTRUM OF GEOMETRIC CORRECTION METHOD OF 
METOPROLOL SUCCINATE IN 0.1M HCL WITH ARTIFICIAL URINE 
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FIGURE-22 
OVERLAID SPECTRUM OF GEOMETRIC CORRECTION METHOD OF 
TELMISARTAN IN 0.1M HCL WITH ARTIFICIAL URINE 
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FIGURE-23 
OVERLAID SPECTRUM OF GEOMETRIC CORRECTION METHOD OF 
METOPROLOL SUCCINATE AND TELMISARTAN IN 0.1M HCL WITH 
ARTIFICIAL URINE 
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FIGURE-24 
CALIBRATION CURVE FOR METOPROLOL SUCCINATE AT 217,225,232 nm 
(GEOMETRIC CORRECTTION METHOD) 
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FIGURE-25 
CALIBRATION CURVE FOR METOPROLOL SUCCINATE AT 267,275,283 nm 
(GEOMETRIC CORRECTTION METHOD) 
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FIGURE-26 
CALIBRATION CURVE FOR TELMISARTAN AT 217,225,232 nm 
(GEOMETRIC CORRECTTION METHOD)  
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FIGURE-27 
CALIBRATION CURVE FOR TELMISARTAN AT 267,275,283 nm 
(GEOMETRIC CORRECTTION METHOD)  
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FIGURE-28 
WAVELENGTH SELECTION FOR RP-HPLC METHOD 
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FIGURE-29 
 
LINEARITY CHROMATOGRAM OF METOPROLOL SUCCINATE AND 
TELMISARTAN-1 (30, 48 µgmL-1) 
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FIGURE-30 
 
LINEARITY CHROMATOGRAM OF METOPROLOL SUCCINATE AND 
TELMISARTAN-2 (40, 64 µgmL-1) 
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FIGURE-31 
 
LINEARITY CHROMATOGRAM OF METOPROLOL SUCCINATE AND 
TELMISARTAN-3 (50, 80 µgmL-1) 
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FIGURE-32 
 
LINEARITY CHROMATOGRAM OF METOPROLOL SUCCINATE AND 
TELMISARTAN-4 (60, 96 µgmL-1) 
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FIGURE-33 
 
LINEARITY CHROMATOGRAM OF METOPROLOL SUCCINATE AND 
TELMISARTAN-5 (70, 112 µgmL-1) 
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FIGURE-34 
CALIBRATION CURVE OF METOPROLOL SUCCINATE BY RP – HPLC 
METHOD 
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FIGURE-35 
CALIBRATION CURVE OF TELMISARTAN BY RP – HPLC METHOD 
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FIGURE-36 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION (METOSARTAN-25) 
REPEATABILITY- 1 
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FIGURE-37 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION (METOSARTAN-25) 
REPEATABILITY- 2 
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FIGURE-38 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION (METOSARTAN-25) 
REPEATABILITY- 3 
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FIGURE-39 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION (METOSARTAN-25) 
REPEATABILITY- 4 
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FIGURE-40 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION (METOSARTAN-25) 
REPEATABILITY- 5 
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FIGURE-41 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION (METOSARTAN-25) 
REPEATABILITY- 6 
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FIGURE – 42 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION (METOSARTAN-25) 
RECOVERY-1 
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FIGURE – 43 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION (METOSARTAN-25) 
RECOVERY-2 
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FIGURE – 44 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION (METOSARTAN-25) 
RECOVERY-3 
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FIGURE-45 
WAVELENGTH SELECTION FOR HPTLC METHOD 
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FIGURE –46 
LINEARITY CHROMATOGRAM OF METOPROLOL SUCCINATE AND 
TELMISARTAN BY HPTLC METHOD-1 [1, 1.6 µgmL-1] 
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FIGURE –47  
LINEARITY CHROMATOGRAM OF METOPROLOL SUCCINATE AND 
TELMISARTAN BY HPTLC METHOD [2, 3.2 µgmL-1] 
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FIGURE –48 
LINEARITY CHROMATOGRAM OF METOPROLOL SUCCINATE AND 
TELMISARTAN BY HPTLC METHOD [3, 4.8 µgmL-1] 
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FIGURE –49 
LINEARITY CHROMATOGRAM OF METOPROLOL SUCCINATE AND 
TELMISARTAN BY HPTLC METHOD [4, 6.4 µgmL-1] 
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FIGURE –50 
LINEARITY CHROMATOGRAM OF METOPROLOL SUCCINATE AND 
TELMISARTAN BY HPTLC METHOD [5, 8 µgmL-1] 
 
 
 
 
 
 
 
 
 
143 
 
FIGURE –51 
SPECTRUM OF METOPROLOL SUCCINATE AND TELMISARTAN IN 
ALL THE TRACKS 
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FIGURE –52  
CALIBRATION CURVE OF METOPROLOL SUCCINATE AT 233 NM BY 
HPTLC METHOD 
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FIGURE –53 
CALIBRATION CURVE OF TELMISARTAN AT 233 NM BY HPTLC METHOD 
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FIGURE-54 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION (METOSARTAN-25) 
REPEATABILITY- 1 
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FIGURE-55 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION (METOSARTAN-25) 
REPEATABILITY- 2 
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FIGURE-56 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION (METOSARTAN-25) 
REPEATABILITY- 3 
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FIGURE-57 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION (METOSARTAN-25) 
REPEATABILITY- 4 
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FIGURE-58 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION (METOSARTAN-25) 
REPEATABILITY- 5 
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FIGURE-59 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION (METOSARTAN-25) 
REPEATABILITY- 6 
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FIGURE – 60 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION 
(METOSARTAN-25) 80% 
RECOVERY-1 
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FIGURE – 61 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION 
(METOSARTAN-25) 100% 
RECOVERY-2 
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FIGURE – 62 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION 
(METOSARTAN-25) 
RECOVERY-3 
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FIGURE-63 
DIFFERENCE BETWEEN SHORTER AND LONGER 
WAVELENGTH OF METOPROLOL SUCCINATE AND 
TELMISARTAN BY HPTLC METHOD 
Shorter wavelength at 254 nm 
 
 
 
Longer wavelength at 366 nm  
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TABLE-1 
 
SOLUBILITY PROFILE OF METOPROLOL SUCCINATE  
 
 
S.No. 
 
SOLVENTS 
 
EXTENT OF SOLUBILITY 
 
SOLUBILITY STATUS 
1 Distilled water 10 mg in .02 ml Freely soluble 
2 0.1M Hydrochloric acid 10 mg in 0.2 ml Soluble 
3 0.1M Sodium Hydroxide 10 mg in 0.5 ml Sparingly soluble 
4 Methanol 10 mg in 0.3ml  Soluble 
5 Ethanol 10 mg in 1.4 ml Slightly soluble 
6 n – Butanol 10 mg in 0.6 ml Sparingly soluble 
7 Chloroform 10 mg in 0.7 ml Sparingly soluble 
8 DMF 10 mg in 5 ml Slightly  soluble 
9 Acetone 10 mg in 2 ml Slightly soluble  
10 Dilute acetic acid  10 mg in 0.4 ml Sparingly soluble 
11 Ethyl acetate 10 mg in 0.5 ml Sparingly soluble  
12 Petroleum ether 10 mg in MT 10 ml Insoluble 
13 Toluene 10 mg in 10 ml Insoluble 
14 Carbon tetra chloride 10 mg in 5 ml Slightly  soluble  
15 Acetonitrile 10 mg in 3 ml Slightly soluble 
16 Benzene 10 mg in MT 10 ml Insoluble  
17 Dichloromethane 10 mg in 9 ml Slightly soluble  
18 n-Hexane 10 mg in MT 10 ml Insoluble 
19 IPA 10 mg in 3 ml Slightly soluble 
20 Acetate buffer pH-3.5 10 mg in MT100 ml Insoluble 
21 Acetate buffer pH-6.0 10 mg in MT 100 ml Insoluble 
22 Phosphate buffer pH – 6.0 10 mg in 1 ml Sparingly soluble  
23 Phosphate buffer pH – 7.0 10 mg in 0.5ml Sparingly soluble 
24 Phosphate buffer pH – 8.0 10 mg in 0.2 ml Soluble 
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TABLE-2 
 
SOLUBILITY PROFILE OF TELMISARTAN  
 
 
S.No. 
 
SOLVENTS 
 
EXTENT OF SOLUBILITY 
 
SOLUBILITY STATUS 
1 Distilled water 10 mg in MT100 ml In soluble 
2 0.1M Hydrochloric acid 10 mg in 2.5 ml Slightly soluble 
3 0.1M Sodium Hydroxide 10 mg in 2 ml Slightly soluble 
4 Methanol 10 mg in 2 ml  Slightly soluble  
5 Ethanol 10 mg in 8 ml Slightly soluble 
6 n – Butanol 10 mg in 7 ml Slightly soluble  
7 Chloroform 10 mg in 9 ml Slightly soluble 
8 DMF 10 mg in 7 ml Slightly  soluble 
9 Acetone 10 mg in 4 ml Slightly soluble  
10 Dilute acetic acid  10 mg in MT 10ml Insoluble 
11 Ethyl acetate 10 mg in 13ml  Very slightly soluble  
12 Petroleum ether 10 mg in MT 10 ml Insoluble 
13 Toluene 10 mg in MT10 ml Insoluble 
14 Carbon tetra chloride 10 mg in MT 10 ml Insoluble  
15 Acetonitrile 10 mg in MT 10 ml Insoluble 
16 Benzene 10 mg in MT 10 ml Insoluble  
17 Dichloromethane 10 mg in 9 ml Slightly soluble  
18 n-Hexane 10 mg in MT 10 ml Insoluble 
19 IPA 10 mg in 4 ml Slightly soluble 
20 Acetate buffer pH-3.5 10 mg in 1.5 ml Slightly soluble  
21 Acetate buffer pH-6.0 10 mg in 3ml Slightly soluble  
22 Phosphate buffer pH – 6.0 10 mg in 100ml Insoluble  
23 Phosphate buffer pH – 7.0 10 mg in MT 100ml Insoluble 
24 Phosphate buffer pH – 8.0 10 mg in 15 ml Very slightly soluble 
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TABLE-3 
MELTING POINT DETERMINATION 
 
 
 
                                                                   
 
 
 
 
 
 
 
 
 
 
S.NO DRUG NAME METING POINT AVERAGE 
VALUE 
MELTING 
POINT 
RANGE 
 
 
 
1. 
 
 
 
  METOPROLOL 
SUCCINATE 
 
1360C 
1360C 
1370C 
1360C 
1370C 
1360C 
 
 
 
136.330C 
 
 
 
 
 
136-1370C 
 
 
 
 
 
2. 
 
 
 
TELMISARTAN 
 
2620C 
2620C 
2600C 
2620C 
2600C 
2620C  
 
 
 
261.330C 
 
 
 
 
 
261-2630C 
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TABLE-4 
 
OPTICAL CHARACTERISTICS OF METOPROLOL SUCCINATE 
BY (SIMULTANEOUS EQUATION METHOD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO 
 
PARAMETERS 
 
 
METOPROLOL 
SUCCINATE  
at 275 nm 
 
METOPROLOL 
SUCCINATE  
at 228.5 nm 
 
1. 
 
Beer’s law limits 
 
 
2-10 µg/ml 
 
2-10 µg/ml 
 
2. 
 
Molar absorptivity 
(L/mol/cm) 
 
 
3973.065143 
 
16396.05638 
 
3. 
 
Slope (m) 
 
 
0.00606904 
 
0.025073571 
 
4. 
 
Intercept (c) 
 
 
0.000171429 
 
0.000429365 
 
5. 
 
Correlation- 
Co-efficient (r) 
 
 
0.999890784 
 
0.999924063 
 
6. 
 
Regression Equation 
(Y=mx+c)  
Y=0.00606904x 
+0.000171429 
 
Y=0.025073571x 
+0.000429365  
 
7. 
 
Sandell’s sensitivity 
(µg/cm²/0.001 A.U) 
 
0.165511438 
 
0.040313539 
 
8. 
 
LOD 
 
 
0.19543612 
 
0.143342449 
 
9. 
 
 
LOQ 
 
 
0.59220668 
 
0.434371057 
 
10. 
 
 
Standard Error 
 
 
0.000364089 
 
0.000087190 
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TABLE-5 
 
OPTICAL CHARACTERISTICS OF  
                   TELMISARTAN BY (SIMULTANEOUS EQUATION METHOD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO 
 
PARAMETERS 
 
 
TELMISARTAN 
at 275 nm 
 
TELMISARTAN 
at 228.5 nm 
 
1. 
 
Beer’s law limits 
 
 
2-10 µg/ml 
 
2-10 µg/ml 
 
2. 
 
Molar absorptivity 
(L/mol/cm) 
 
 
27591.30003 
 
53815.31603 
 
3. 
 
Slope (m) 
 
 
0.035626349 
 
0.140126825 
 
4. 
 
Intercept (c) 
 
 
0.00174656 
 
0.004501587 
 
5. 
 
Correlation- 
Co-efficient (r) 
 
 
0.99993 
 
0.99991 
 
5. 
 
Regression Equation 
(Y=mx+c)  
Y=0.035626349x 
+0.00174656 
Y=0.140126825 
+0.004501587 
 
6. 
 
Sandell’s sensitivity 
(µg/cm²/0.001 A.U) 
 
0.02815996 
 
0.009669374 
 
7. 
 
LOD 
 
 
0.235200495 
 
0.192697579 
 
8. 
 
 
LOQ 
 
 
0.712728772 
 
0.583932059 
 
9. 
 
 
Standard Error 
 
 
0.002576656 
 
0.008650838 
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TABLE- 6 
QUANTIFICATION OF FORMULATION (METOSARTAN-25) BY  
SIMULTANEOUS EQUATION METHOD 
 
Drug 
Sample 
No. 
Labeled 
amount 
(mgtab-1) 
Amount 
found 
(mgtab-1)* 
Percentage 
Obtained* 
Average 
(%) 
S.D. 
% 
R.S.D. 
S.E. 
 
 
 
 
MET 
 
 
1 
2 
3 
4 
5 
6 
 
25 
25 
25 
25 
25 
25 
 
25.34 
25.54 
25.12 
24.67 
25.11 
25.34 
 
101.38 
102.18 
100.48 
98.68 
100.44 
101.38 
 
 
 
100.76  
 
 
 
 
1.2076 
 
 
 
 
1.1986 
 
 
 
 
0.033546 
 
 
 
 
 
TEL 
 
 
 
1 
2 
3 
4 
5 
6          
 
40 
40 
40 
40 
40 
40 
 
40.28 
40.22 
40.33 
40.41 
40.35 
40.28 
 
100.71 
100.55 
100.81 
101.03 
100.88 
100.71                       
 
 
 
100.78 
 
 
 
 
 
0.1649 
 
 
 
0.01637 
 
 
 
 
 
 
0.00458 
 
 
 
 
* Mean of six observations 
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TABLE-7 
INTRA DAY AND INTER DAY ANALYSIS OF 50 % PREANALYZED FORMULATION (METOSARTAN-25) BY 
SIMULTANEOUS EQUATION METHOD 
 
 
Drug 
perc
enta
ge 
 
Amount 
present* 
(µg mL-1) 
 
Amount 
added 
(µg mL-1) 
 
Amount 
estimated* 
(µg mL-1) 
  
Amount 
recovered* 
(µg mL-1) 
 
% Recovery* 
 
 
S.D. 
 
% 
R.S.D. 
 
 
 
S.E. 
 
 
 
 
MET 
 
 
 
 
80 
 
100 
 
120 
Intra Inter Intra Inter Intra Inter Intra Inter Intra Inter Intra Inter Intra Inter Intra Inter 
 
 
2 
 
2 
 
2 
 
 
2 
 
2 
 
2 
 
 
3.2 
 
4 
 
4.8 
 
 
3.2 
 
4 
 
4.8 
 
 
5.25 
 
6.02 
 
6.79 
 
 
5.24 
 
6.00 
 
6.78 
 
 
3.25 
 
4.02 
 
4.79 
 
 
3.24 
 
4.00 
 
4.78 
 
 
101.56 
 
100.50 
 
99.79 
 
 
101.25 
 
100.00 
 
99.58 
 
 
 
0.890
749 
 
 
 
 
 
0.868
696 
 
 
 
0.885
289 
 
 
 
 
 
0.866
3 
 
 
 
0.098
972 
 
 
 
 
 
0.096
522 
 
 
 
 
TEL 
 
 
 
80 
 
100 
 
120 
 
3.2 
 
3.2 
 
3.2 
 
3.2 
 
3.2 
 
3.2 
 
5.12 
 
6.4 
 
7.68 
 
5.12 
 
6.4 
 
7.68 
 
8.37 
 
9.69 
 
11.00 
 
8.37 
 
9.69 
 
11.00 
 
5.17 
 
6.49 
 
7.80 
 
5.17 
 
6.49 
 
7.80 
 
100.98 
 
101.41 
 
101.56 
 
100.98 
 
101.41 
 
101.56 
 
 
 
0.301
054 
 
 
 
 
 
0.301
054 
 
 
 
0.271
41 
 
 
 
0.297
141 
 
 
 
 
0.033
45 
 
 
 
 
 
 
 
0.033
45 
 
 
* Mean of Three Observations
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TABLE-8 
RUGGEDNESS STUDIES OF 50 % PREANALYZED FORMULATION  
(METOSARTAN-25) BY SIMULTANEOUS EQUATION METHOD  
   
 
 
 
 
*Mean of six observations 
 
 
 
 
 
 
 
Drug percentage Condition % Recovery* S.D 
% 
R.S.D 
S.E. 
 
 
 
MET 
 
 
 
 
 
 
80 
 
 
100 
 
 
120 
 
Analyst 1 
Analyst 2 
 
Analyst 1 
Analyst 2 
 
Analyst 1 
Analyst 2 
 
 
 
100.32 
101.98 
 
100.00 
101.25 
 
99.52 
100.00 
 
0.6100 
0.1732 
 
0.4330 
1.0000 
 
0.6361 
0.3637 
 
0.6080 
0.1698 
 
0.4330 
0.9876 
 
0.6392 
0.3637 
 
0.0381 
0.0192 
 
0.0481 
0.1111 
 
0.0706 
0.04042 
 
 
 
TEL 
 
 
 
        
80 
 
 
100 
 
 
120 
 
Analyst 1 
Analyst 2 
 
Analyst 1 
Analyst 2 
 
Analyst 1 
Analyst 2 
 
 
101.11 
101.04 
 
100.95 
101.32 
 
101.41 
101.62 
 
 
0.1154 
0.1097 
 
1.1001 
0.2020 
 
0.1328 
0.2821 
 
0.1142 
0.1085 
 
1.0897 
0.6206 
 
0.1309 
0.2777 
 
0.01283 
0.01218 
 
0.1222 
0.0224 
 
0.0147 
0.0313 
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TABLE -9 
RECOVERY STUDIES OF 50 % PREANALYZED FORMULATION  
(METOSARTAN-25) BY SIMULTANEOUS EQUATION METHOD 
Drug percentage 
Amount 
present* 
(µg mL-1) 
Amount 
added 
(µg mL-1) 
Amount 
estimated* 
(µg mL-1) 
Amount 
recovered* 
(µg mL-1) 
% Recovery* 
Average 
(%) 
± S.D. 
% 
R.S.D. 
S.E. 
 
 
 
MET 
 
 
80 
 
100 
 
120 
 
2 
 
2 
 
2 
 
3.2 
 
4 
 
4.8 
 
5.21 
 
6 
 
6.78 
 
3.21 
 
4 
 
4.78 
 
100.22 
 
100.00 
 
99.52 
 
 
99.91 
± 
0.3579 
 
  
 
 
 
0.3582 
 
 
 
 
 
 0.03977 
 
 
 
 
 
TEL 
 
 
 
80 
 
100 
 
120 
 
 
3.2 
 
3.2 
 
3.2 
 
5.12 
 
6.4 
 
7.68 
 
8.38 
 
9.69 
 
10.99 
 
5.18 
 
6.46 
 
7.79 
 
101.05 
 
100.95 
 
101.41 
 
 
101.28 
± 
0.2419 
 
 
    
   
 
 0.2392 
   
 
 
 
0.02688 
 
 
 
* Mean of Three Observations
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TABLE-10 
 
OPTICAL CHARACTERISTICS OF METOPROLOL SUCCINATE 
BY (AREA UNDER CURVE METHOD) 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
S.NO 
 
PARAMETERS 
 
 
METOPROLOL 
SUCCINATE  
at 227.5-214 nm 
 
METOPROLOL 
SUCCINATE  
at 303-278.5nm 
 
1. 
 
Beer’s law limits 
 
 
2-10 µg/ml 
 
2-10 µg/ml 
 
2. 
 
Molar absorptivity 
(L/mol/cm) 
 
 
329219.6297 
 
35945.44762 
 
3. 
 
Slope (m) 
 
 
0.502610238 
 
0.055014762 
 
4. 
 
Intercept (c) 
 
 
0.017690476 
 
0.000487302 
 
5. 
 
Correlation- 
Co-efficient (r) 
 
 
0.9999 
 
0.9999 
 
6. 
 
Regression Equation 
(Y=mx+c)  
Y=0.502610238x 
+0.017690476  
Y=0.055014762x 
+0.000487302 
 
7. 
 
Sandell’s sensitivity 
(µg/cm²/0.001 A.U) 
 
0.002000426 
 
0.01822363 
 
8. 
 
LOD 
 
 
0.05869901 
 
0.143102643 
 
9. 
 
 
LOQ 
 
 
0.177875788 
 
0.433102643 
 
10. 
 
 
Standard Error 
 
 
0.02657721 
 
0.00269465 
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TABLE-11 
 
OPTICAL CHARACTERISTICS OF 
TELMISARTAN BY (AREA UNDER CURVE METHOD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO 
 
PARAMETERS 
 
 
TELMISARTAN 
at 227.5-214 nm 
 
TELMISARTAN 
At 303-278.5 nm 
 
1. 
 
Beer’s law limits 
 
 
2-10 µg/ml 
 
2-10 µg/ml 
 
2. 
 
Molar absorptivity 
(L/mol/cm) 
 
 
672549.3228 
 
613867.9328 
 
3. 
 
Slope (m) 
 
 
1.295958889 
 
1.184860159 
 
4. 
 
Intercept (c) 
 
 
0.109772222 
 
0.080429365 
 
5. 
 
Correlation- 
Co-efficient (r) 
 
 
0.999912089 
 
0.999878024 
 
5. 
 
Regression Equation 
(Y=mx+c)  
Y=1.295958889x 
    +0.109772222  
Y=1.184860159x 
+0.080429365 
 
6. 
 
Sandell’s sensitivity 
(µg/cm²/0.001 A.U) 
 
0.000774802 
 
0.000847447 
 
7. 
 
LOD 
 
 
0.148839775 
 
0.213862987 
 
8. 
 
 
LOQ 
 
 
0.451029621 
 
0.648069658 
 
9. 
 
 
Standard Error 
 
 
0.107476858 
 
0.107247113 
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TABLE- 12 
QUANTIFICATION OF FORMULATION (METOSARTAN-25) BY  
AREA UNDER CUVRE METHOD  
 
Drug 
Sample 
No. 
Labeled 
amount 
(mgtab-1) 
Amount found 
(mgtab-1)* 
Percentage 
Obtained* 
Average 
(%) 
S.D. 
% 
R.S.D. 
S.E. 
 
 
 
 
MET 
 
 
1 
2 
3 
4 
5 
6 
 
25 
25 
25 
25 
25 
25 
 
25.17 
25.10 
24.79 
24.79 
24.79 
24.92 
 
100.68 
100.43 
99.16 
99.16 
99.16 
99.68 
 
 
 
99.71  
 
 
 
 
0.68814 
 
 
 
 
0.69013 
 
 
 
 
0.019115 
 
 
 
 
 
TEL 
 
 
 
1 
2 
3 
4 
5 
6          
 
40 
40 
40 
40 
40 
40 
 
39.77 
39.78 
40.03 
40.03 
39.97 
39.98 
 
99.43 
99.45 
100.09 
100.09 
99.93 
99.95                       
 
 
 
99.82 
 
 
 
 
 
 
0.304543 
 
 
 
0.305082 
 
 
 
 
 
 
0.00846 
 
 
 
 
*Mean of six observations 
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TABLE-13 
INTRA DAY AND INTER DAY ANALYSIS OF 50 % PREANALYZED FORMULATION (METOSARTAN-25) BY AREA 
UNDER CUVRE METHOD 
 
 
Drug 
perc
enta
ge 
 
Amount 
present* 
(µg mL-1) 
 
Amount 
added 
(µg mL-1) 
 
Amount 
estimated* 
(µg mL-1) 
 
 Amount 
recovered* 
(µg mL-1) 
 
% Recovery* 
 
S.D. 
% 
R.S.D. 
 
S.E. 
 
 
 
 
MET 
 
 
 
 
80 
 
100 
 
120 
Intra Inter Intra Inter Intra Inter Intra Inter Intra Inter Intra Inter Intra Inter Intra Inter 
 
 
2 
 
2 
 
2 
 
 
2 
 
2 
 
2 
 
 
3.2 
 
4 
 
4.8 
 
 
3.2 
 
4 
 
4.8 
 
 
5.21 
 
6.08 
 
6.96 
 
 
5.21 
 
6.06 
 
6.99 
 
 
3.21 
 
4.08 
 
4.96 
 
 
3.21 
 
4.06 
 
4.99 
 
 
100.31 
 
102.00 
 
103.30 
 
 
100.31 
 
101.50 
 
103.30 
 
 
 
 
1.499
2 
 
 
 
 
 
 
1.505
3 
 
 
 
 
1.471
7 
 
 
 
 
 
 
1.480
1 
 
 
 
 
0.166
581 
 
 
 
 
 
 
0.166
7259 
 
 
 
 
TEL 
 
 
 
80 
 
100 
 
120 
 
 
3.2 
 
3.2 
 
3.2 
 
3.2 
 
3.2 
 
3.2 
 
5.12 
 
6.4 
 
7.68 
 
5.12 
 
6.4 
 
7.68 
 
8.29 
 
9.56 
 
10.83 
 
8.29 
 
9.56 
 
10.83 
 
5.09 
 
6.36 
 
7.63 
 
5.09 
 
6.36 
 
7.63 
 
99.41 
 
99.38 
 
99.35 
 
99.41 
 
99.38 
 
99.359 
 
 
 
0.030
000 
 
 
 
 
 
0.030
000 
 
 
 
0.030
187 
 
 
 
0.030
187 
 
 
 
 
0.003
333 
 
 
 
 
 
 
 
0.003
333 
 
 
 
 
 
* Mean of Three Observations 
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TABLE-14 
 
RUGGEDNESS STUDIES OF 50 % PREANALYZED FORMULATION  
(METOSARTAN-25) BY AREA UNDER CUVRE METHOD 
 
 
 
 
*Mean of six observations 
 
 
 
 
 
Drug percentage Condition % Recovery* S.D 
% 
R.S.D 
S.E. 
 
 
 
MET 
 
 
 
 
 
 
80 
 
 
100 
 
 
120 
 
Analyst 1 
Analyst 2 
 
Analyst 1 
Analyst 2 
 
Analyst 1 
Analyst 2 
 
 
 
100.10 
100.31 
 
100.92 
101.25 
 
102.99 
99.79 
 
0.3579 
0.4033 
 
1.4648 
0.4330 
 
0.8653 
0.2032 
 
0.3575 
0.4027 
 
1.4515 
0.4276 
 
          0.8402 
           0.2019 
 
0.0397 
0.0375 
 
0.1627 
0.0481 
 
0.0961 
0.0252 
 
 
 
TEL 
 
 
 
        
80 
 
 
100 
 
 
120 
 
Analyst 1 
Analyst 2 
 
Analyst 1 
Analyst 2 
 
Analyst 1 
Analyst 2 
 
 
99.39 
99.41 
 
98.97 
99.43 
 
99.52 
100.52 
 
 
0.0346 
0.6051 
 
0.4592 
0.0866 
 
0.1985 
0.7032 
 
0.0348 
0.6038 
 
0.4640 
0.0870 
 
0.1995 
           0.7029 
 
0.0038 
0.0593 
 
0.0510 
0.0096 
 
0.0220 
0.0221 
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TABLE -15 
RECOVERY STUDIES OF 50 % PREANALYZED FORMULATION  
(METOSARTAN-25) BY AREA UNDER CURVE METHOD 
Drug percentage 
Amount 
present* 
(µg mL-1) 
Amount 
added 
(µg mL-1) 
Amount 
estimated* 
(µg mL-1) 
Amount 
recovered* 
(µg mL-1) 
% Recovery* 
Average 
(%) 
± S.D. 
% 
R.S.D. 
S.E. 
 
 
 
MET 
 
 
80 
 
100 
 
120 
 
2 
 
2 
 
2 
 
3.2 
 
4 
 
6.4 
 
      5.20 
 
6.04 
 
6.97 
 
3.20 
 
4.04 
 
4.97 
 
100.10 
 
100.92 
 
102.99 
 
 
101.34 
± 
1.4893 
 
  
 
 
 
1.4697 
 
 
 
 
 
 0.1654 
 
 
 
 
 
TEL 
 
 
 
80 
 
100 
 
120 
 
 
3.2 
 
3.2 
 
3.2 
 
5.12 
 
6.4 
 
7.68 
 
8.29 
 
9.54 
 
10.84 
 
5.09 
 
6.34 
 
7.64 
 
99.39 
 
99.09 
 
99.52 
 
 
99.33 
± 
0.2205 
 
 
    
   
 
 0.2220 
   
 
 
 
0.0245 
 
 
* Mean of Three Observations 
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TABLE-16 
OPTICACHARACTERISTICS OF METOPROLOL SUCCINATE AND 
TELMISARTAN BY (FIRST ORDER DERIVATIVE 
 SPECTROPHOTOMETRIC METHOD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO 
 
PARAMETERS 
 
 
METOPROLOL 
SUCCINATE 
at 269 nm 
 
TELMISARTAN 
at 243 nm 
 
1. 
 
Beer’s law limits 
 
 
10-50 µg/ml 
 
16-80 µg/ml 
 
2. 
 
Molar absorptivity 
(L/mol/cm) 
 
 
130.0937143 
 
1166.475676 
 
3. 
 
Slope (m) 
 
 
0.00019381 
 
0.002168349 
 
4. 
 
Intercept (c) 
 
 
0.0000547619 
 
0.000984127 
 
5. 
 
Correlation- 
Co-efficient (r) 
 
 
0.9998 
 
0.9999 
 
5. 
 
Regression Equation 
(Y=mx+c)  
Y=0.00019381x 
+0.0000547619 
Y=0.002168349x 
+0.000984127 
 
6. 
 
Sandell’s sensitivity 
(µg/cm²/0.001 A.U) 
 
5.161626985 
 
0.461561591 
 
7. 
 
LOD 
 
 
0.099303638 
 
0.303226499 
 
8. 
 
 
LOQ 
 
 
0.30092116 
 
0.918868178 
 
9. 
 
 
Standard Error 
 
 
0.00000556425 
 
0.000897122 
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                                                               TABLE- 17 
QUANTIFICATION OF FORMULATION (METOSARTAN-25) BY  
FIRST ORDER DERIVATIVE SPECTROPHOTOMETRIC METHOD  
 
Drug 
Sample 
No. 
Labeled 
amount 
(mgtab-1) 
Amount found 
(mgtab-1)* 
Percentage 
Obtained* 
Average 
(%) 
S.D. 
% 
R.S.D. 
S.E. 
 
 
 
 
MET 
 
 
1 
2 
3 
4 
5 
6 
 
25 
25 
25 
25 
25 
25 
 
25.47 
25.47 
24.82 
25.47 
25.17 
24.87 
 
101.88 
101.88 
99.28 
101.88 
101.88 
99.28 
 
 
 
101.01  
 
 
 
 
1.34263 
 
 
 
 
1.32916 
 
 
 
 
0.037295 
 
 
 
 
 
TEL 
 
 
 
1 
2 
3 
4 
5 
6          
 
40 
40 
40 
40 
40 
40 
 
40.79 
40.74 
40.45 
39.65 
40.62 
40.62 
 
101.99 
101.85 
101.13 
99.12 
101.55 
101.55                       
 
 
 
101.19 
 
 
 
 
 
 
1.06046 
 
 
 
1.04790 
 
 
 
 
 
 
0.029457 
 
 
 
 
* Mean of six observations 
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TABLE-18 
INTRA DAY AND INTER DAY ANALYSIS OF 50 % PREANALYZED FORMULATION (METOSARTAN-25) BY FIRST 
ORDER DERIVATIVE SPECTROPHOTOMETRIC METHOD 
 
 
Drug 
perc
enta
ge 
 
Amount 
present* 
(µg mL-1) 
 
Amount 
added 
(µg mL-1) 
 
Amount 
estimated* 
(µg mL-1) 
 
 Amount 
recovered* 
(µg mL-1) 
 
% Recovery* 
 
S.D. 
% 
R.S.D. 
 
S.E. 
 
 
 
 
MET 
 
 
 
 
80 
 
100 
 
120 
Intra Inter Intra Inter Intra Inter Intra Inter Intra Inter Intra Inter Intra Inter Intra Inter 
 
 
10 
 
10 
 
10 
 
 
10 
 
10 
 
10 
 
 
16 
 
20 
 
24 
 
 
16 
 
20 
 
24 
 
 
26.23 
 
30.19 
 
34.15 
 
 
26.07 
 
30.02 
 
34.15 
 
 
16.23 
 
20.02 
 
24.15 
 
 
16.07 
 
20.02 
 
24.15 
 
 
101.44 
 
100.95 
 
100.63 
 
 
100.44 
 
100.01 
 
100.63 
 
 
 
 
0.407
962 
 
 
 
 
 
 
0.317
648 
 
 
 
 
0.403
897 
 
 
 
 
 
 
0.316
508 
 
 
 
 
0.045
329 
 
 
 
 
 
 
0.035
294 
 
 
 
 
TEL 
 
 
 
80 
 
100 
 
120 
 
 
16 
 
16 
 
16 
 
16 
 
16 
 
16 
 
25.6 
 
32 
 
38.4 
 
25.6 
 
32 
 
38.4 
 
41.61 
 
48.2 
 
54.61 
 
41.62 
 
48.06 
 
54.63 
 
25.61 
 
32.20 
 
38.61 
 
25.62 
 
32.06 
 
38.63 
 
100.98 
 
101.41 
 
101.56 
 
100.08 
 
100.19 
 
100.59 
 
 
 
0.320
052 
 
 
 
 
 
0.268
39 
 
 
 
0.318
756 
 
 
 
0.267
623 
 
 
 
 
0.035
561 
 
 
 
 
 
 
 
0.029
821 
 
 
 
 
 
            * Mean of Three Observations 
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TABLE-19 
RUGGEDNESS STUDIES OF 50 % PREANALYZED FORMULATION 
(METOSARTAN-25) BY FIRST ORDER DERIVATIVE 
SPECTROPHOTOMETRIC METHOD 
 
 
 
*Mean of six observations 
 
 
 
 
 
 
Drug percentage Condition % Recovery* S.D 
% 
R.S.D 
S.E. 
 
 
 
MET 
 
 
 
 
 
 
80 
 
 
100 
 
 
120 
 
Analyst 1 
Analyst 2 
 
Analyst 1 
Analyst 2 
 
Analyst 1 
Analyst 2 
 
 
 
101.46 
100.44 
 
100.10 
100.10 
 
100.62 
100.62 
 
1.7666 
1.3024 
 
1.4722 
1.4722 
 
1.2239 
1.2239 
 
1.7412 
1.3019 
 
1.4707 
1.4707 
 
1.2164 
1.2164 
 
0.1963 
0.1534 
 
0.1635 
0.1635 
 
0.1359 
0.1359 
 
 
 
TEL 
 
 
 
        
80 
 
 
100 
 
 
120 
 
Analyst 1 
Analyst 2 
 
Analyst 1 
Analyst 2 
 
Analyst 1 
Analyst 2 
 
 
99.96 
100.02 
 
100.85 
100.18 
 
100.47 
100.55 
 
 
0.4355 
0.1756 
 
1.4923 
0.3837 
 
0.2594 
0.1300 
 
0.4357 
0.1755 
 
1.4797 
0.3829 
 
0.2582 
0.1293 
 
0.0483 
0.0195 
 
0.1658 
0.0426 
 
0.0288 
0.0144 
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TABLE -20 
RECOVERY STUDIES OF 50 % PREANALYZED FORMULATION  
(METOSARTAN-25) BY FIRST ORDER DERIVATIVE  
SPECTROPHOTOMETRIC METHOD 
Drug percentage 
Amount 
present* 
(µg mL-1) 
Amount 
added 
(µg mL-1) 
Amount 
estimated* 
(µg mL-1) 
Amount 
recovered* 
(µg mL-1) 
% Recovery* 
Average 
(%) 
± S.D. 
% 
R.S.D. 
S.E. 
 
 
 
MET 
 
 
80 
 
100 
 
120 
 
10 
 
10 
 
10 
 
16 
 
20 
 
24 
 
      26.23 
 
30.02 
 
34.15 
 
16.23 
 
20.02 
 
24.15 
 
101.46 
 
100.10 
 
100.62 
 
 
100.72 
± 
0.6862 
 
  
 
 
 
0.6813 
 
 
 
 
 
 0.07625 
 
 
 
 
 
TEL 
 
 
 
80 
 
100 
 
120 
 
 
16 
 
16 
 
16 
 
25.6 
 
32 
 
38.4 
 
41.59 
 
48.27 
 
54.58 
 
25.59 
 
32.27 
 
38.58 
 
99.96 
 
100.85 
 
100.47 
 
 
100.42 
± 
0.4465 
 
 
    
   
 
 0.4446 
   
 
 
 
0.04962 
 
 
 
* Mean of Three Observations 
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TABLE-21 
 
OPTICAL CHARACTERISTICS OF 
METOPROLOL SUCCINATE BY (GEOMETRIC CORRECTION METHOD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
S.NO 
 
PARAMETER
S 
 
 
METOPROLOL 
SUCCINATE 
at 217,225,232 nm 
 
METOPROLOL 
SUCCINATE 
at 267,275,283 nm 
 
1. 
 
Beer’s law limits 
 
 
2-10 µg/ml 
 
2-10 µg/ml 
 
2. 
 
Molar absorptivity 
(L/mol/cm) 
 
 
4328290 
 
7038444 
 
3. 
 
Slope (m) 
 
 
6.595441 
 
-10.9788 
 
 
4. 
 
Intercept (c) 
 
 
0.352474 
 
15.74788 
 
 
5. 
 
Correlation- 
Co-efficient (r) 
 
 
0.992645 
 
 
0.9918 
 
 
6. 
Regression 
Equation 
(Y=mx+c)  
Y=6.595441x 
+ 0.352474 
         Y=10.9788x 
+15.74788 
 
7. 
 
Sandell’s 
sensitivity 
(µg/cm²/0.001 A.U) 
 
0.000154 
 
-0.000095 
 
8. 
 
LOD 
 
 
0.174649 
 
0.59185 
 
 
9. 
 
 
LOQ 
 
 
0.52924 
 
 
1.79349 
 
10. 
 
 
Standard Error 
 
 
0.065919 
 
0.0435 
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TABLE-22 
 
OPTICAL CHARACTERISTICS OF 
TELMISARTAN BY (GEOMETRIC CORRECTION METHOD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO 
 
PARAMETER
S 
 
 
TELMISARTAN 
at 217,225,232 nm 
 
TELMISARTAN 
at 267,275,283 nm 
 
1. 
 
Beer’s law limits 
 
 
3.2-16 µg/ml 
 
3.2-16 µg/ml 
 
2. 
Molar absorptivity 
(L/mol/cm) 
 
2684981 
 
8809124 
 
3. 
 
Slope (m) 
 
5.23179 
 
17.06563 
 
4. 
 
Intercept (c) 
 
4.148641 
 
-1.96577 
 
5. 
 
Correlation- 
Co-efficient (r) 
 
0.99479 
 
0.993169 
 
6. 
Regression 
Equation 
(Y=mx+c)  
       Y=5.23179x 
      +4.148641 
 
Y=17.06563x 
+1.96577 
 
7. 
Sandell’s 
sensitivity 
(µg/cm²/0.001 A.U) 
 
0.00019 
 
0.0000608 
 
 
8. 
 
LOD 
 
 
0.08945 
 
0.102019 
 
9. 
 
 
LOQ 
 
 
0.27105 
 
0.30915 
 
10. 
 
 
Standard Error 
 
 
0.068482 
 
0.025638 
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TABLE- 23 
QUANTIFICATION OF FORMULATION (METOSARTAN-25) BY  
GEOMETRIC CORRECTION METHOD  
 
Drug 
Sample 
No. 
Labeled 
amount 
(mgtab-1) 
Amount found 
(mgtab-1)* 
Percentage 
Obtained* 
Average 
(%) 
S.D. 
% 
R.S.D. 
S.E. 
 
 
 
 
MET 
 
 
1 
2 
3 
4 
5 
6 
 
25 
25 
25 
25 
25 
25 
 
25.04 
24.92 
24.98 
24.92 
25.11 
25.04 
 
100.16 
99.68 
99.92 
99.68 
100.44 
100.16 
 
 
 
100.00 
 
 
 
 
0.3019 
 
 
 
 
0.3018 
 
 
 
 
0.0083 
 
 
 
 
 
TEL 
 
 
 
1 
2 
3 
4 
5 
6          
 
40 
40 
40 
40 
40 
40 
 
40.28 
40.09 
40.03 
40.03 
39.91 
40.09 
 
100.70 
100.23 
100.07 
100.07 
99.77 
100.23                       
 
 
 
100.17 
 
 
 
 
 
 
0.3058 
 
 
 
 
0.3052 
 
 
 
 
 
 
0.0084 
 
 
 
 
*Mean of six observations 
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TABLE -24 
RECOVERY STUDIES OF 50 % PREANALYZED FORMULATION  
(METOSARTAN-25) BY GEOMETRIC CORRECTION METHOD 
Drug percentage 
Amount 
present* 
(µg mL-1) 
Amount 
added 
(µg mL-1) 
Amount 
estimated* 
(µg mL-1) 
Amount 
recovered* 
(µg mL-1) 
% Recovery* 
Average 
(%) 
± S.D. 
% 
R.S.D. 
S.E. 
 
 
 
MET 
 
 
80 
 
100 
 
120 
 
2 
 
2 
 
2 
 
3.2 
 
4 
 
6.4 
 
      5.20 
 
5.97 
 
6.81 
 
3.20 
 
3.97 
 
4.81 
 
100.11 
 
99.25 
 
100.28 
 
 
99.88 
± 
0.5521 
 
  
 
 
 
0.5528 
 
 
 
 
 
0.0613 
 
 
 
 
 
TEL 
 
 
 
80 
 
100 
 
120 
 
3.2 
 
3.2 
 
3.2 
 
5.12 
 
6.4 
 
7.68 
 
8.34 
 
9.60 
 
10.88 
 
5.14 
 
6.40 
 
7.68 
 
100.39 
 
100.04 
 
100.00 
 
 
100.14 
± 
0.2145 
 
 
    
   
 
0.2142 
   
 
 
 
0.0238 
 
 
 
 
*Mean of three observations 
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                                                            TABLE -25 
SYSTEM SUITABILITY PARAMETERS FOR THE OPTIMIZED 
 CHROMATOGRAM BY RP – HPLC METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO PARAMETERS 
(specifications as per ICH 
guidelines) 
METOPROLOL 
SUCCINATE 
TELMISARTAN 
 
1. Tailing factor (≤ 2) 1.5 1.25 
 
2. Asymmetrical factor (≤ 2) 2 1.33 
 
3. Capacity factor (> 2.0) 0.52 3.47 
 
4. Theoretical plate per unit length 
50.99 197.08 
 
5. Theoretical plates (>2000) 764.86 2956.19 
 
6. 
Resolution (> 2)                                        7.05 
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TABLE-26 
OPTICAL CHARECTERSTICS OF METOPROLOL SUCCINATE AND 
TELMISARTAN (RP-HPLC METHOD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO 
 
PARAMETERS 
 
 
METOPROLOL 
SUCCINATE 
at 230 nm 
 
TELMISARTAN 
at 230 nm 
 
1. 
 
Beer’s law limits 
 
 
30-70 µg/ml 
 
48-112 µg/ml 
 
2. 
 
Molar absorptivity 
(L/mol/cm) 
 
 
6985886.506 
 
40477589.52 
 
3. 
 
Slope (m) 
 
 
11.80776378 
 
87.32922264 
 
4. 
 
Intercept (c) 
 
 
11.0639369 
 
86.70867568 
 
5. 
 
Correlation- 
Co-efficient (r) 
 
 
0.9990 
 
0.9994 
 
5. 
 
Regression Equation 
(Y=mx+c)  
Y=11.80776378x 
      +11.0639369 
Y=87.32922264x 
+86.70867568 
 
6. 
 
LOD 
 
 
0.006488491 
 
0.001988734 
 
7. 
 
 
LOQ 
 
 
0.019662102 
 
0.006026466 
 
8. 
 
 
Standard Error 
 
 
14.60533931 
 
128.6548409 
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TABLE-27 
 
ASSAY OF FORMULATION (METOSARTAN-25) BY RP – HPLC METHOD 
 
  
*Mean of six observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug 
Sam
ple 
No. 
Labeled 
amount 
(mgtab-1) 
Amount 
found 
(mgtab-1)* 
Percentage 
Obtained* 
Average 
(%) 
S.D. 
% 
R.S.D. 
S.E. 
 
 
 
MET 
 
1 
2 
3 
4 
5 
6 
 
 
 
25 mg 
 
 
24.93 
25.17 
25.12 
25.02 
24.88 
24.91 
 
99.72 
100.68 
100.48 
100.09 
99.52 
99.66 
 
 
 
100.02 
 
 
 
0.4736 
 
 
 
 
0.4734 
 
 
 
0.0132 
 
 
 
 
 
TEL 
 
 
1 
2 
3 
4 
5 
6 
 
 
 
40 mg 
 
39.58 
39.75 
39.62 
39.84 
39.69 
39.91 
 
98.94 
99.37 
99.04 
99.59 
99.23 
99.77 
 
 
 
99.33 
 
 
 
0.3189 
 
 
 
0.3211 
 
 
 
0.0089 
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TABLE -28 
 
RECOVERY STUDIES OF FOEMULATION BY RP – HPLC METHOD 
 
*Mean of three observations 
 
 
 
 
 
 
 
 
 
Drug Percentage 
Amount 
present 
(µg/ml) 
Amount 
added 
(µg/ml) 
Amount 
estimated 
(µg/ml) 
Amount 
recovered 
(µg/ml) 
% 
Recovery 
 
Average 
(%) 
±  
S.D 
% 
R.S.D 
 
S.E 
 
 
 
 
MET 
 
80 
 
100 
 
 
 
120 
 
30 
 
30 
 
30 
 
 
25 
 
30 
 
35 
 
54.85 
 
60.54 
 
64.84 
 
 
25.48 
 
31.06 
 
35.69 
 
 
101.92 
 
103.53 
 
101.97 
 
 
102.47 
± 
0.9154 
 
 
 
 
0.8933 
 
 
 
 
 
 
 
0.1017 
 
 
 
 
 
 
 
TEL 
 
 
 
80 
 
 
100 
 
 
120 
 
48 
 
48 
 
          48 
 
 
38.4 
 
48 
 
57.6 
 
 
85.99 
 
96.24 
 
105.19 
 
 
37.99 
 
48.24 
 
57.19 
 
 
98.93 
 
100.05 
 
99.28 
 
 
99.42 
± 
0.5729 
 
 
 
0.5763 
 
 
 
 
 
 
0.0636 
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TABLE -29 
OPTICAL CHARACTERISTICS OF METOPROLOL SUCCINATE AND  
TELMISARTAN BY HPTLC METHOD 
                                      
S.NO PARAMETERS 
METOPROLOL 
SUCCINATE at 
233nm 
TELMISARTAN 
at 233nm 
1 Beer’s law limit (µg/ml) 1-5 1.6 – 8  
2 Correlation Coefficient (r) 0.9995 0.9998 
3 Regression Equation  (y=mx+c) y =469.3 x+338      y =1155x+ 1.706 
4 Slope (m) 469.3  1155 
5 Intercept (c) 338 1.706 
6 Standard Deviation                         2.10 0.75 
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TABLE-30 
 
ASSAY OF FORMULATION (METOSARTAN-25) BY HPTLC METHOD 
 
  
*Mean of six observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug 
Sam
ple 
No. 
Labeled 
amount 
(mgtab-1) 
Amount 
found 
(mgtab-1)* 
Percentage 
Obtained* 
Average 
(%) 
S.D. 
% 
R.S.D. 
S.E. 
 
 
 
MET 
 
1 
2 
3 
4 
5 
6 
 
 
 
25 mg 
 
 
24.82 
24.89 
24,85 
25.05 
25.09 
24.73 
 
99.28 
99.59 
99.39 
100.21 
       100.34 
98.91 
 
 
 
99.62 
 
 
 
0.5549 
 
 
 
 
0.5570 
 
 
 
0.0616 
 
 
 
 
 
TEL 
 
 
 
1 
2 
3 
4 
5 
6 
 
 
 
40 mg 
 
40.12 
40.22 
40.02 
39.88 
40.82 
39.77 
 
100.31 
100.57 
100.05 
99.72 
102.05 
99.44 
 
 
 
100.35 
 
 
 
0.9224 
 
 
 
0.9191 
 
 
 
0.1024 
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TABLE -31 
 
RECOVERY STUDIES OF FOEMULATION (METOSARTAN-25) BY 
HPTLC METHOD 
 
*Mean of three observations 
 
 
 
 
 
 
Drug Sample. No 
Amount 
present 
(µg/ml) 
Amount 
added 
(µg/ml) 
Amount 
estimated 
(µg/ml) 
Amount 
recovered 
(µg/ml) 
% 
Recovery 
 
Average 
(%) 
±  
S.D 
% 
R.S.D 
 
S.E 
 
 
MET 
 
1 
2 
3 
 
 
 
 
 
1 
1 
1 
 
 
 
1.6 
2 
2.4 
 
 
2.61 
3.07 
3.41 
 
 
 
1.61 
2.07 
2.41 
 
 
 
100.62 
103.50 
100.41 
 
 
 
101.51 
± 
1.7265 
 
 
 
 
1.7009 
 
 
 
 
 
 
0.1918 
 
 
 
 
 
 
TEL 
 
 
1 
2 
3 
 
 
1.6 
1.6 
1.6 
 
 
 
 
2.56 
3.2 
3.84 
 
 
 
 
3.58 
4.22 
4.85 
 
 
 
 
          2.58 
3.22 
3.85 
 
 
 
 
100.78 
100.62 
100.26 
 
 
 
 
100.55 
± 
0.2663 
 
 
 
0.2648 
 
 
 
 
 
0.0295 
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